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Background: Hereditary Non-Polyposis Colorectal Cancer (HNPCC) is a dominantly inherited 
syndrome predisposing individuals to cancers of the colon and other organs. HNPCC is caused 
by mutations in one of four mismatch repair proteins responsible for DNA repair. Current 
guidelines on HNPCC screening have focused on administering molecular testing on tumors of 
at-risk groups affected with colorectal cancer. Criteria for molecular testing include both tumor 
pathology and personal and family history of cancer. Abnormal tumor test results warrant 
referral for genetic counseling and germline testing. Public Health Significance: Identifying 
individuals with HNPCC is crucial for screening and surgical purposes in order to reduce 
mortality and morbidity. Additionally, at-risk family members can undergo germline testing to 
determine whether increased surveillance or surgery is warranted. Results: The study revealed 
that 45.3% (total n=44) of patients warranting genetic counseling attended at a genetic 
counseling appointment within the UPMC system. Patients who had a personal or family history 
of cancer were more likely to attend a genetic counseling session than individuals who had 
pathological or age dependant risk factors (p = 0.0014; OR = 4.8; 95% CI: 1.78, 12.95). 
Furthermore, patients with a family history of colorectal cancer were more likely to attend a 
genetic counseling session than individuals whose families displayed a different type of cancer. 
The average time interval between molecular tumor testing and genetic counseling was 
 iv 
 
approximately 63 days. Finally, 24% and 21.5% of individuals with abnormal tumor results were 
identified independently by family history and pathological criteria, respectively. Conclusions: 
This study indicates that improvements can be made in genetic counseling referral process for at-
risk HNPCC individuals within the UPMC system. Several factors were potentially associated 
with attending a genetic counseling session including: the presence of personal or family cancer 
history, and type of cancers in the family. Timing may also impact attendance with a genetic 
counselor. The study reveals that there is an opportunity for more detailed family history 
collection within the UPMC system, from which health care practitioners can identify and 
address factors that may influence patient compliance with genetic counseling referrals and 
clinical management.   These results can also inform development of a state-wide screening 
program. 
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1.0  BACKGROUND 
Colon cancer affects approximately 145,000 individuals in the United States per year and is the 
fourth most commonly diagnosed cancer in the United States, but ranks second amongst cancer 
deaths (Hampel, Frankel et al. 2008; ACS 2011; Ahnen 2011). The lifetime risk of developing 
colorectal cancer is approximately 5%, with nearly half of those diagnosed succumbing to the 
disease (Terdiman, Conrad et al. 1999; Grady 2003). The cause of colorectal cancer can be 
environmental or genetically influenced, with a proportion generated by a combination of both 
components. 
Several factors contribute to the development of colorectal cancer including biological, 
physical, environmental and genetic aspects. Biological characteristics that amplify the risk of 
colorectal cancer are increased age and race; nearly 90% of individuals diagnosed with colon 
cancer are over the age of 50 and higher rates of cancer are seen in the African American and 
Caucasian population (NCI 2011). Additionally, a personal history of inflammatory bowel 
disease and colorectal polyps increases an individual’s risk for colorectal cancer. Physical factors 
such as an inactive lifestyle, diets high in fat, calories, and alcohol consumption and smoking 
have been associated with an increased risk for colorectal cancer (Rose, Boyar et al. 1986; 
Martinez, Giovannucci et al. 1997; Slattery, Potter et al. 1997; Cho, Smith-Warner et al. 2004). 
Those with hereditary colon cancer syndrome and those with family members who have had 
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colorectal cancer show an increased risk for developing colorectal cancer at higher frequencies 
and at earlier ages than individuals without genetic risk factors (Burt 2000).  
1.1 GENETICS OF COLON CANCER 
According to Vogelstein and Fearon, colorectal tumorigenesis is a multistep process, beginning 
with somatic mutations, resulting in cellular abnormalities and corresponding uncontrolled cell 
growth. Since Vogelstein and Fearon proposed their model, our understanding of colon cancer 
carcinogenesis has grown exponentially, due to a greater pathological and molecular 
comprehension of the disease. One way to characterize colon cancer development is based on the 
initiating pathway, either the tumor suppressor pathway or the mutator pathway. The 
classification can also be dependent on the precursor lesion from which the cancer derives; in the 
adenoma-carcinoma pathway, the cancer progresses from conventional adenomas, and in the 
serrated pathway, cancers originate from lesions such as serrated sessile adenomas and polyps 
(Snover 2011). 
Cancers arising from the tumor suppressor pathway are the result of somatic or germline 
mutations occurring in genes responsible for cell cycle control. Several genes are frequently 
mutated in the tumor suppressor pathway, and mutations in these genes are often observed in a 
sequential pattern dependent on the stage of tumor development. This succession of mutations in 
relation to the stage of the cancer is supported by studies that document that inactivation of the 
adenomatous polyposis coli (APC) gene and mutations in the KRAS oncogene occurred earlier in 
the sequence, whereas mutations in tumor suppressor genes, such as p53, occur more frequently 
later in the progression (Vogelstein, Fearon et al. 1989; Snover 2011). Tumors arising from the 
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tumor suppressor pathway have distinct histological characteristics and typically have a 
territorial advantage; these tumors are genetically unstable, resulting in losses or gains of 
chromosome arms, chromosomal translocation or gene amplification, and are appropriately 
referred to as chromosomal instable tumors (CIN) comprising the majority of observed colorectal 
cancers (Vogelstein, Fearon et al. 1989).  
Mutator pathway tumors are the result of mutations in mutator genes, which lead to an 
increased rate of somatic mutations in other genes. A number of mutator pathway tumors derive 
from mutations in mismatch repairs (MMR) genes, which are responsible for DNA base repair 
and promote development of tumors by increasing the number of mutations in other regulatory 
cell cycle genes or those involved in carcinogenesis (Halling, Harper et al. 1999). Tumors arising 
from the mutator pathway do not display the same territorial advantage as CIN tumors, and thus 
have a better prognosis. Tumors arising as a result of a defect in the mismatch repair system 
typically display a unique characteristic known as microsatellite instability (MSI). 
Microsatellites are found throughout the genome and are comprised of repetitive DNA 
sequences. The DNA repeats are typically mono- and dinucleic repetitions, however, higher 
order repeats are also observed.  As a result of the repetitive nature of their structure, 
microsatellites are prone to the formation of DNA hairpins causing deletions and duplication 
errors and base-base mismatches (Vilar and Gruber 2010). The mismatch repair (MMR) genes 
are primarily responsible for repairing such errors, therefore, an impediment in the functionality 
of these proteins results in an accumulation of errors. When subsequent mutations occur in cell 
cycle regulatory genes it can result in the development of tumors. As a result, microsatellite 
instability, the presence of contraction or expansion in the repeated regions, is commonly 
observed in MMR deficient tumors (Syngal, Fox et al. 2000). However, microsatellite instable 
 4 
tumors maintain karyotypic stability and are observed in 5-15% of all colorectal cancers, with 
the majority being sporadic in nature (Fearon and Vogelstein 1990; Rodriguez-Bigas, Boland et 
al. 1997; Bedeir and Krasinskas 2011; Snover 2011).  
The serrated pathway has been used to describe cancers that arise from mutations that 
lead to CpG island methylation. Methylation-induced silencing of genes is believed to account 
for the progression from pre-cursor lesion to carcinogenesis, with the morphology and rate of 
progression dependant on the genes that are affected (Snover 2011). Alternative mechanisms of 
the serrated pathway have been described, however, the veracity of these mechanisms have not 
been molecularly confirmed (Snover 2011). 
There is significant overlap between the proposed mechanisms of colorectal 
carcinogenesis. A large proportion of tumors arising from the adenoma-carcinoma sequence have 
been observed to derive from the tumor suppressor pathway, with some seen as a result of the 
mutator pathway. A proportion of sessile serrated adenomas and polyps that develop into cancer 
have been documented to originate from the mutator pathway and display microsatellite 
instability, while others do not (Jass 2003; Jass 2005; Snover 2011). 
1.2 HEREDITARY CANCERS 
Comprehensive models of cancer development have allowed investigators to target genes that 
might play a role in hereditary predisposition for colon cancer. Studies involving individuals 
possessing germline mutation in oncogenes or tumor suppressor genes involved in colon 
carcinogenesis have identified numerous hereditary syndromes associated with an increased risk 
of colon cancer. Hereditary forms of cancer are associated with approximately 5-10% of all 
 5 
cancers observed (Nagy, Sweet et al. 2004). Hereditary colorectal cancer syndromes have often 
been categorized into two groups: polyposis and non-polyposis forms.  
Polyposis refers to the presence of multiple polyps that can be localized or distributed 
throughout the colon. As individuals with a hereditary polyposis syndrome have an increased 
number of polyps and adenomas compared to the general population, they are at an increased 
risk for colorectal cancer development through the adenoma-carcinogensis pathway. Hereditary 
polyposis syndromes can be inherited in a dominant or recessive manner, and are responsible for 
less than 1% of all colorectal cancers observed (Bedeir and Krasinskas 2011). Examples of 
hereditary polyposis syndromes include Familial Adenomatous Polyposis (FAP) and Attenuated 
Familial Adenomatous Polyposis (AFAP), which both arise from mutations in the APC gene, as 
well as Juvenile Polyposis (JP), MUTYH-Associated Polyposis (MAP) and Peutz-Jegher 
Syndrome (PJS). The polyposis syndromes are often differentiated from one another 
pathologically, although with the variety of syndromes and range of polyp subtypes, ambiguity 
still remains. The number and distribution of polyps, as well as molecular and genetic testing, 
can aid with uncertainties and risk assessment for family members (Roessner, Kuester et al. 
2011). However, as a result of the heterogeneity of many hereditary cancer syndromes, cancer 
risk values can range significantly for each syndrome (Vasen 2000).  
Alternatively, the term non-polyposis has been formulated in order to distinguish 
syndromes different from the polyposis syndromes. Non-polyposis refers to the absence of 
polyps or the presence of very few polyps. The most common hereditary predisposition to 
colorectal cancer devoid of multiple polyps or adenomas is known as Hereditary Non-Polyposis 
Colorectal Cancer (HNPCC), or often referred to as Lynch Syndrome (Senter, Clendenning et al. 
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2008). HNPCC accounts for approximately 2-5% of all colorectal cancer observed (Hampel, 
Frankel et al. 2005) 
 
 7 
2.0  HEREDITARY NON-POLYPOSIS COLORECTAL CANCER 
Hereditary non-polyposis colorectal cancer (HNPCC) syndrome was first reported by Aldred 
Warthin in 1931, who described a family with a pattern of gastric and endometrial cancer. 
However, it was Henry Lynch’s work that led to the development of a more comprehensive 
clinical picture of the syndrome (Nagy, Sweet et al. 2004). As a result, the term HNPCC has 
often been used interchangeably with Lynch syndrome. However, it has been recognized that 
only those individuals who have undergone genetic testing and have an identified germline 
mutation have Lynch syndrome, while others are referred to as having HNPCC.  
HNPCC is a dominant genetic condition resulting in an increased risk for colorectal and 
endometrial cancer. Additionally, HNPCC individuals have an increased risk for other cancers 
including those of the stomach, ovaries, small intestine, biliary tract and pancreas, urinary tract, 
as well as brain and sebaceous tumors (Vasen, Wijnen et al. 1996; Rodriguez-Bigas, Vasen et al. 
1998; Aarnio, Sankila et al. 1999; Park, Shin et al. 2000; Senter, Clendenning et al. 2008; 
Watson, Vasen et al. 2008).  As HNPCC involves multiple organ systems, it can overlap with 
other hereditary cancer syndromes, which makes identifying individuals with the syndrome 
difficult. One example of such obscurity is seen in certain HNPCC families presenting with brain 
tumors, most commonly glioblastomas, who are described as having a subphenotype of HNPCC 
known as Turcot syndrome (Hamilton, Liu et al. 1995). Further complicating matters, Turcot 
syndrome is also used to describe a subset of families with Familial Adenomatous Polyposis 
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(FAP), another hereditary colon cancer syndrome. An additional subclassification of HNPCC is 
observed in families presenting with skin findings such as keratoacanthomas and sebaceous skin 
tumors, known as Muir-Torre syndrome (Ollila, Fitzpatrick et al. 2006). 
2.1 CAUSE 
HNPCC is caused by germline mutations in mismatch repair (MMR) genes whose expressed 
proteins are responsible for DNA single-base pair excision repair. Dysfunction in these genes can 
lead to increased mutations in cancer inducing genes.  The MMR genes implicated in HNPCC 
are the mutl homolog 1(MLH1), mutS homolog 2 (MSH2), mutS homolog 6 (MSH6) and 
postmeiotic segregation increased 2 (PMS2) genes; other MMR genes, such as PMS1 and MLH3, 
may also play a role, but they have not been well established (Syngal, Fox et al. 2000; Umar, 
Boland et al. 2004; Senter, Clendenning et al. 2008). Additionally, TGFBR2, and EXO1 have 
been implicated as potential causes of HNPCC, but are still under investigation (Grady 2003).  
Analysis of the MMR protein function shows that MLH1 and PMS2 form heterodimers, as do 
MSH2 and MSH6. These structures are responsible for base-base mismatch repair or reparation 
of DNA hairpin loops that can occur as a result of DNA slippage. In HNPCC individuals, the 
most commonly mutated DNA mismatch repair genes are MLH1 and MSH2 (Syngal, Fox et al. 
2000), and mutations in these two genes have a greater cancer risk compared to other MMR 
genes due to increased penetrance. MLH1 is able to form heterodimers with MLH3 and PMS1 in 
the absence of PMS2, while MSH2 can combine with MSH3 in absence of MSH6 (Vilar and 
Gruber 2010). Consequently, mutations resulting in non-functioning PMS2 or MSH6 proteins 
carry less risk as MMR functionality can be maintained through alternative binding.  
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Mutations in MSH2 accounts for approximately 38% of mutations identified in 
individuals with HNPCC, followed by MLH1 with 32%, and both MSH6 and PMS2 mutations 
are observed around 15% of the time (Hampel, Frankel et al. 2005; Senter, Clendenning et al. 
2008). Alternative mechanisms for hereditary deficiency in MMR functionality have been 
evaluated.  Studies indicate that approximately 20-25% of individuals whose colorectal tumor 
display a loss of function of MSH2 or MSH6, without an identified germline mutation, have a 
deletion in the EPCAM/TACSD1 gene. The EPCAM/TACSD1 gene is found upstream from 
MSH2 and mutations in the gene have been found to result in the hypermethylation of the MSH2 
promoter region, reducing its expression (Ligtenberg, Kuiper et al. 2009; Rumilla, Schowalter et 
al. 2011). As a result, this mechanism is proposed to account for approximately 5% of all Lynch 
syndrome tumors with abnormal MSH2/MSH6 testing. 
2.2 CANCER RISKS 
2.2.1 COLORECTAL CANCER 
HNPCC, like other hereditary cancer syndromes, is associated with an earlier age of cancer 
diagnosis. Individuals with HNPCC are typically diagnosed with colorectal cancer between 42 
and 61 years of age, compared to 71 years of age in the general population (Hampel, Frankel et 
al. 2005; Horner 2009; Stoffel, Mukherjee et al. 2009).  
The overall risks for colorectal cancer in individuals with HNPCC range from 20% to 
74% by age 70. Gender differences in colorectal cancer risks have also been reported in the 
HNPCC population with women having as low as 30-40% less risk compared to men (Hampel, 
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Frankel et al. 2005; Stoffel, Mukherjee et al. 2009). Cancer risks can be contingent on the MMR 
gene affected. Lynch syndrome individuals with MSH6 mutation appear to have lower risks 
compared to Lynch syndrome individuals with mutation in other MMR genes. Men with MSH6 
mutations have a 22% chance of developing colorectal cancer, while women have a 10% chance 
of developing the same type of cancer. Similarly, PMS2 mutation carriers also have reduced 
colorectal cancer risks including a 20% and 15% risk for males and females, respectively 
(Senter, Clendenning et al. 2008). 
2.2.2 ENDOMETRIAL CANCER 
Women with HNPCC have a 26-42% lifetime risk for endometrial cancer with some studies 
indicating a risk as high as 80% (Hampel, Frankel et al. 2005; Senter, Clendenning et al. 2008; 
Stoffel, Mukherjee et al. 2009). Phenotype-genotype associations have also been observed in 
endometrial cancers in women with HNPCC as female MSH6 mutation carriers having a lower 
risk (26%) of developing endometrial cancer (Senter, Clendenning et al. 2008). Additionally, 
female PMS2 mutation carriers’ risk for endometrial cancer is approximately 15% (Senter, 
Clendenning et al. 2008). 
2.2.3 OTHER CANCERS 
Increased risks for upper urinary tract, ovarian, gastric, small bowel, biliary tract, pancreatic and 
brain cancers have been associated with HNPCC. Cancer risks in these other organs vary greatly, 
but are generally considered to be less than 10-15% (Vasen, Moslein et al. 2007). A large study 
attempted to quantify risks with greater precision and concluded that the risk for urinary tract 
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cancer is highest with an approximate 8% lifetime risk, with men at greater risk than women. It 
was also found that women have a 7% lifetime risk for ovarian cancer. They concluded that the 
next most prevalent cancer is gastric cancer with a 5.4% lifetime risk, followed by small bowel 
cancer at 4% and biliary tract/pancreatic cancer at 4%. Individuals with HNPCC have a 2% 
lifetime risk for brain cancer, however, its association with HNPCC remains cloudy as early age 
of onset and high mortality rates make mutation testing difficult. The authors also revealed that 
MSH2 mutation carriers have a higher risk compared to MLH1 mutations carriers when assessing 
incidence of cancers outside of colon and endometrial cancers (Watson, Vasen et al. 2008). 
HNPCC individuals have a 30% risk of developing a second cancer within 10 years of the first 
cancer diagnosis and this number increases to 50% at 15 years post diagnosis (Lynch, Harris et 
al. 1977; Mecklin and Jarvinen 1986). 
In rare circumstances, biallelic PMS2 loss has been reported and is a distinct syndrome 
resulting in hematologic and gastrointestinal malignancies and brain tumors at younger ages than 
those with Lynch syndrome. Biallelic PMS2 loss results in features similar to 
Neurofibromatosis-1, including café-au-lait spots, which are also categorically disparate from 
Lynch syndrome individuals (Senter, Clendenning et al. 2008). Additionally, individuals with 
Muir Torre, often identified by the presence of specific skin findings, are more frequently 
observed to have germline mutations in MSH2 compared to the other MMR genes (South, 
Hampel et al. 2008). 
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2.3 DETECTION ON HNPCC INDIVIDUALS 
Identifying individuals with HNPCC is an essential public health issue because of its 
implications regarding surveillance, prognosis, surgical management, treatment and follow-up 
for patients and their at-risk family members (Rodriguez-Bigas, Boland et al. 1997). Determining 
the most efficient method of identifying individuals with HNPCC remains a widely debated 
issue. Population genetic screening for HNPCC is expensive and time-consuming, therefore, 
efforts have been focused on constructing an algorithm to distinguish high-risk HNPCC 
individuals from the general population. Multiple factors have been proposed or implemented 
including family history, tumor pathology, molecular and/or protein staining testing (Rodriguez-
Bigas, Boland et al. 1997). 
2.3.1 Family History 
HNPCC was originally identified through observational studies identifying cancer patterns 
within families, and was originally described as the diagnosis of endometrial and colorectal 
cancers presenting at an early age, or as a general familial clustering of colorectal and other types 
of cancer (Vasen 2000). As a result, several family history models have been proposed for the 
general screening for Lynch Syndrome (Dinh, Rosner et al. 2011). The model currently 
implemented most frequently in clinic, the Amsterdam Criteria, is used to identify high-risk 
individuals and families. As our knowledge of the syndrome has increased, the family history 
model has been altered in order to improve its efficacy.  
Initially, the International Collaborative Group (ICG) proposed a family history based set 
of guidelines to identify at-risk individuals for HNPCC. The first version of the Amsterdam 
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Criteria, published in 1990, stated that the presence of three family members with colorectal 
cancer (with one individual being a first-degree relative to the other two, and one of the cancers 
diagnosed prior to age of 50), met a clinical diagnosis of HNPCC (Vasen, Mecklin et al. 1991). 
However, evaluations of the model proved it to be inefficient and the Amsterdam Criteria has 
been heavily criticized for its stringency. Evaluations of the model showed low levels of 
specificity and sensitivity for MLH1 and MSH2 mutation carriers, at 61% and 67%, respectively, 
indicating a need to improve the criteria (Rodriguez-Bigas, Boland et al. 1997; Syngal, Fox et al. 
2000).  
In order to address limitations in the Amsterdam Criteria including those with small 
families and those with extracolonic cancers, the Modified Amsterdam criteria was drafted. The 
Modified Amsterdam criteria considered small families with two affected first-degree relatives, 
with one diagnosed prior to age 55, and a third family member with endometrial cancer or 
another early neoplasm (Bellacosa, Genuardi et al. 1996). The new criteria improved the 
sensitivity to 72%, still far from ideal (Syngal, Fox et al. 2000). 
In 1999, the International Collaborative Group expanded the Amsterdam Criteria to 
include those with associated HNPCC cancers. As a result, individuals diagnosed with 
colorectal, endometrial, small bowel, ureter, or renal pelvis cancer were included within the 
confines of the original Amsterdam conditions (Vasen, Watson et al. 1999). The revised clinical 
diagnostic criteria was aptly named Amsterdam Criteria II and increased the sensitivity to 87% 
and 62% for identifying MLH1 and MSH2 mutation carriers respectively. Sensitivities for the 
less prevalent MSH6 and PMS2 were still lacking with documented values of 38% and 48%, 
respectively (Syngal, Fox et al. 2000; Sjursen, Haukanes et al. 2010).  
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After extensive evaluation, it became obvious that the Amsterdam Criteria could not be 
utilized as a paradigm, but more as a framework in an attempt to incorporate characteristics 
observed across several reports. Nonetheless, the use of family history models as a way to 
identify HNPCC individuals in a clinical setting has been met with resistance, with many citing 
that the use of family history as the sole tool for identifying HNPCC individuals is not an 
effective method. The effectiveness of the method is not only limited by the lack of an 
unequivocal presentation, but also by other factors including small families, cases of adoption, 
non-paternity, denial of cancer diagnosis within the family, and families that are geographically 
or communicatively disconnected from one another, make collecting family histories an 
unreliable instrument for this purpose. Data suggests that a large proportion of individuals 
underreport the presence of colorectal cancers in first-degree relatives and an even greater 
inaccuracy was observed regarding second-degree relatives (Mitchell, Brewster et al. 2004). 
Therefore, poor patient recall of family cancer history may lead to an underrepresentation of 
families meeting clinical hereditary cancer syndrome criteria, specifically the Amsterdam 
criteria. Additionally, surgical removal of tissues at risk to develop cancer can reduce penetrance 
of the disease. Therefore, as attempts to identify unaffected individuals at risk for carrying a 
germline MMR mutation using family history alone have been largely unsuccessful, detection of 
HNPCC individuals has been reduced to molecular testing of affected individuals. 
Once the genetic cause of HNPCC had been identified, it became less complicated to 
identify common attributes associated with the syndrome. Consequently, studies identifying 
prevalent HNPCC features were initiated to refine the search criteria of affected individuals. 
Studies suggested that 8.4% of individuals diagnosed with colorectal cancer under the age of 50 
were identified as having Lynch syndrome (Hampel, Frankel et al. 2008), characterizing this as a 
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high-risk group that required increased attention. However, more recent data showed that nearly 
half of individuals with Lynch Syndrome are diagnosed over the age of 50 (Hampel, Frankel et 
al. 2008). Thus, testing that was limited to only those with early cancer diagnosis would miss a 
substantial portion of individuals with the syndrome and it could not be the sole criteria. 
2.3.2 Microsatellite Instability 
Additional studies have been carried out to identify histopathological markers that correlate with 
HNPCC individuals so as to improve the identification of these individuals. A significant finding 
associated with HNPCC is microsatellite instability. Approximately, 8-20% of all colorectal 
cancers in the United States test positive for microsatellite instability (MSI-H).  The phenotype 
occurs as a result of somatic, germline or epigenetic changes affecting mismatch repair genes 
(Herman, Umar et al. 1998; Hampel, Frankel et al. 2005; Ligtenberg, Kuiper et al. 2009). The 
presence of microsatellite instability in HNPCC tumors has lead to further investigation of the 
motif. Data suggests that approximately 95% of microsatellite instable colorectal tumors of 
HNPCC syndrome patients are a result of loss of expression of one of the four MMR genes, 
while 5% of these tumors have an unknown reason for their microsatellite instability (Lynch, 
Shaw et al. 2004). Furthermore, microsatellite instability has been seen in a range of HNPCC 
associated tumors including gastric, endometrial, ovarian and sebaceous carcinomas, 
glioblastomas and lymphomas (Vilar and Gruber 2010).  
Risk models utilizing multiple components, including family history and molecular test 
results, have been created in order to predict the likelihood of an individual carrying a germline 
mutation in an MMR gene as well as cancer risks. Examples of risk models include MMRpro 
which utilizes components such as family history of colorectal and endometrial cancer, age at 
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diagnosis, MSI and IHC results, MLH1, MSH2 and MSH6 mutation prevalence and penetrance, 
and other characteristics to predict carrier status and cancer risk (Chen, Wang et al. 2006). 
Another model, PREMM, accounts for colon, endometrial and other HNPCC-related cancers, 
age at diagnosis, presence of multiple HNPCC cancers in an individual and relationship to the 
proband to predict the probability of carrying an MLH1 or MSH2 mutation (Balmana, Stockwell 
et al. 2006). The model that appears to provide the greatest sensitivity and specificity, is the two-
stage logistical regression model used in MMRpredict (Barnetson, Tenesa et al. 2006). The 
model incorporates proband sex, cancer locations, endometrial cancer of close relatives, age of 
diagnosis and presence of multiple tumors in the first stage, and molecular test results in the 
second stage. 
2.3.3 MSI in Sporadic Cancer 
Microsatellite instability associated with HNPCC patients is also prevalent in sporadic colorectal 
cancer (Cunningham, Christensen et al. 1998). Sporadic MSI-H tumors share similar 
characteristics to HNPCC tumors, but do not follow a hereditary pattern, nor are they observed at 
early ages, and are seen more often in individuals over the age of 70 (Poynter, Haile et al. 2009). 
Sporadic MSI-High colorectal cancers arise from sessile serrated adenomas or polyps, as 
opposed to HNPCC-related colorectal cancer, which are believed to develop from conventional 
adenomas (Loughrey, Waring et al. 2007).  
Sporadic tumors with the MSI-H phenotype are associated with mutations in several 
oncogenes and tumor suppressor genes including MRE11A and KRAS. However, it had been 
determined that the majority of MSI-H sporadic colorectal cancers are the result of 
hypermethylation of the promoter region of the MLH1 gene (Cunningham, Christensen et al. 
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1998). The discovery of the epigenetic pathway associated with the development of sporadic 
MSI tumors lead to the detection of correlations between the BRAF gene and MSI histology 
(Davies, Bignell et al. 2002; Rajagopalan, Bardelli et al. 2002; Ahnen 2011). The BRAF gene is a 
cytoplasmic protein kinase that plays a role in the raF/meK/erK/maPK kinase signaling pathway 
and cellular apoptosis (Snover 2011). An activating mutation in the BRAF gene causes 
hypermethylation of the MLH1 gene, suppressing its expression, which has been corroborated by 
the absence of MLH1 on protein staining tests (Rajagopalan, Bardelli et al. 2002). BRAF 
mutations have been implicated in sporadic melanoma (66%) and other cancers. However, BRAF 
mutations have not been identified in non-colonic HNPCC related tumors with MLH1 
methylation, therefore, BRAF testing for the purposes of excluding HNPCC is limited to 
colorectal cancer tissue (Deng, Bell et al. 2004). The most common mutation identified in the 
BRAF gene is a single nucleotide polymorphism of thymine to adenine in exon 15 resulting in an 
amino acid substitution from a valine to glutamic acid (V600E). The mutation is observed in 
more than 90% of colorectal cancers with a BRAF mutation and found in 31-83% of all sporadic 
MSI colorectal cancers (Rajagopalan, Bardelli et al. 2002; Deng, Bell et al. 2004; Kambara, 
Simms et al. 2004). Studies have shown a strong correlation (87%) to the presence of a BRAF 
mutation in MSI colorectal tumors with MLH1 promoter methylation and a marked absence in 
tumors with germline MLH1 mutations. Individuals with a BRAF mutation are rarely found to 
have concurrent MMR mutations and studies indicate that positive BRAF V600E mutations show 
a high specificity for predicting negative germline mutations in MMR gene testing (Loughrey, 
Waring et al. 2007). For these reasons, testing for the V600E mutation in MSI tumors has been 
adopted as an inexpensive secondary step to discriminate those who do not require more 
laborious MMR gene testing (McGivern, Wynter et al. 2004). Although rare, concurrent 
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mutations in BRAF and MMR genes are possible, therefore, the presence of a BRAF mutation 
does not completely rule out the possibility of HNPCC (Davies, Bignell et al. 2002; Rajagopalan, 
Bardelli et al. 2002; Deng, Bell et al. 2004). 
MSI colorectal tumors with MLH1 promoter methylation without an identified BRAF 
V600E mutation comprise another subgroup of cases. Subsequently, some authors suggest the 
testing of MSI colorectal tumor with absent MLH1 staining for BRAF mutation and, if negative, 
succeeding methylation testing. However, as opposed to the exclusion of HNPCC when a BRAF 
mutation is identified, studies suggest that a small number of individuals within this subset group 
have concurrent germline mutations and unexplained or somatic MLH1 promoter methylation 
(Bouzourene, Hutter et al. 2010). An explanation for this phenomenon has been proposed as the 
result of MMR germline mutations which cause hypermethylation of the wild-type allele. 
Therefore, testing tumors for only MLH1 methylation would result in potential HNPCC 
individuals being missed (Loughrey, Waring et al. 2007). Although the difficulty in excluding all 
HNPCC individuals by BRAF and methylation testing remains, the rare cases of MLH1 
methylation in HNPCC individuals without a BRAF mutation have been described as having less 
robust methylation when compared to sporadic hypermethylated tumors, and this may be a 
potential method to discriminate the two groups (Bouzourene, Hutter et al. 2010).  
Other possible explanations for suppression of gene expression by hypermethylation have 
been proposed which could potentially account for a dysfunctional MMR system. Germline 
epimutations in MLH1 have been identified, resulting in cancers similar to those seen in Lynch 
syndrome (Hitchins and Ward 2009). Studies have implicated elevated levels of 
methyltransferases in hypermethylation of genes, while other literature cites correlations between 
increasing age and methylation at other gene loci (Issa, Ottaviano et al. 1994). Alternative 
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methylation pathways have been documented where studies revealed associations between MSI-
H colorectal tumors and CpG methylation at other loci including p16, IGF2, TSP-1 and HIC-1 
(Ahuja, Mohan et al. 1997).  
Mutations in other genes have also been proposed to explain hypermethylation, 
specifically mutations in the KRAS gene. Both BRAF and KRAS are found in the epidermal 
growth factor (EGF) pathway, therefore, mutations in either would have a similar biological 
effect. As a result, it was anticipated that mutations in both genes would not provide any 
additional biological advantage, and it has been demonstrated that mutations in these two genes 
are mutually exclusive from one another (Ahnen 2011). These findings resulted in the 
recognition that classic adenomas with KRAS mutations were not precursors to sporadic MSI 
colorectal cancers, and lead to the discovery that MSI colorectal cancers derived from serrated 
polyps (Ahnen 2011). The concept of the serrated polyp-carcinoma pathway was a direct result 
of this study, which is distinct from the original adenoma-carcinoma pathway (Ahnen 2011). 
Other approaches have been explored in order to decipher between sporadic and hereditary 
microsatellite unstable tumors. Gene expression studies of MLH1 and PIWIL1 genes, have been 
proposed as potential techniques for differentiating to two subgroups of tumors (Kruhoffer, 
Jensen et al. 2005).  
Differentiating between sporadic and hereditary MSI tumors remains problematical and 
an area of much deliberation. As a result of the phenotypic overlap, current guidelines used to 
determine candidates for MSI testing for the purpose of identifying germline mutations in MMR 
genes, intrinsically identifies a larger proportion of individuals with sporadic MSI-H colorectal 
cancers that do not possess a mutation. It remains imperative that this subset of individuals be 
distinguished in order to avoid needless and costly genetic testing. 
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2.3.4 Microsatellite Stable and Low Microsatellite Instability 
An additional 3-10% of colorectal cancers display low levels of instability (MSI-L), with the 
remainder being microsatellite stable (MSS) tumors (Lynch, Smyrk et al. 1993; Aaltonen, 
Salovaara et al. 1998; Salovaara, Loukola et al. 2000; Hampel, Frankel et al. 2008). Tumors that 
display lower levels of microsatellite instability have been described as MSI-L. The 
classification of MSI-L tumors is determined based on the presence of instability in a panel of 
markers (Aaltonen, Salovaara et al. 1998; Salovaara, Loukola et al. 2000; Hampel, Frankel et al. 
2008). The clinical relevance of MSI-L tumors is not well established and several studies suggest 
that its association with an MMR deficiency is rare. Therefore, the presence of MSI-L tumors in 
an individual is considered to exclude, or make highly unlikely, the existence HNPCC (Mueller, 
Gazzoli et al. 2009). MSH6 mutations have been shown to be associated with MSI-L tumors, 
presenting a predicament in excluding HNPCC based on MSI results. 
2.3.5 Other Pathological Characteristics 
Colorectal tumors with microsatellite instability possess other specific profiles, which can be 
helpful in identifying HNPCC individuals. Data indicates that MSI colorectal tumors are found 
in greater frequency in the right side of the colon, have a lower stage at diagnosis, and have 
higher histological grades. As a result, the ICG suggests that clinicians should be aware of 
characteristics associated with HNPCC colorectal cancer, including an increased proportion of 
cancers found in the proximal colon and the presence of multiple colon cancers, mucinous 
phenotypes with marked tumor-infiltrating lymphocytes, a Crohn’s-like host response and an 
absence of necrotic cellular debris (Vasen, Watson et al. 1999; Greenson, Bonner et al. 2003). A 
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strong association with HNPCC has been observed in tumors displaying mucinous and signet-
ring cell component, with less of a consensus on the presence of tumor infiltrating lymphocytes 
(Wu, Shibata et al. 2001).  
Interestingly, despite the poor prognosis of cancers with pathological characteristics 
commonly seen in Lynch Syndrome colorectal cancer, these cancers typically have a better 
outcome than CIN cancers (Ahnen 2011). Similarly, gynecological cancers in HNPCC syndrome 
individuals are largely diagnosed at an earlier stage and are often curable (Watson, Butzow et al. 
2001). 
2.4 BETHESDA CRITERIA 
The Amsterdam Criteria I have been classically focused on high-risk families and was found to 
be too stringent, therefore a set of criteria using the reported characteristics of HNPCC tumors 
for population-based screening was needed. The National Cancer Institute (NCI) International 
Workshop constructed a set of guidelines, known as the Bethesda Criteria, as a tool to capture a 
greater number of individuals with HNPCC. The guidelines outlined a set of criteria for tumors 
that should be considered for evaluation of microsatellite instability. Based on the results of the 
MSI testing, additional testing or corresponding counseling were suggested.  
When initially constructed, the Bethesda criteria suggested that MSI testing be carried out 
on (Boland, Thibodeau et al. 1998; Pinol, Castells et al. 2005): 
• individuals with cancer that met the Amsterdam criteria 
• those diagnosed with colorectal or endometrial cancer under the age of 45 
• diagnosis of an adenoma in an individual less than 40 years of age 
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• individuals with two HNPCC related cancers (metachronous or synchronous) 
• individuals with colorectal cancer and a first degree relative with either an 
HNPCC related cancer diagnosed under 45 or an adenoma under the age of 40 
• those less than 45 years of age with a right-sided colorectal cancer with 
solid/cribiform histology or a signet ring type colorectal tumor  
Based on the age restrictions suggested for each criterion, there was a reduced 
significance for pathological influence, as any cancer diagnosed under the age of 45 should be 
captured irrespective of tumor characteristic. Studies measuring the quality of the criteria 
indicated a superior sensitivity over the Amsterdam criteria with value of ~94%. However, the 
specificity of the Bethesda criteria was reported to be approximately 25% for identifying 
individuals with an MLH1 or MSH2 germline mutation and 30% for germline mutations in any 
MMR gene (Syngal, Fox et al. 2000; Pinol, Castells et al. 2005).  
As a result of the poor specificity values, the Bethesda Criteria have been revised 
subsequent to an NCI workshop in 2002 and outlined in 2004 (Umar, Boland et al. 2004).  The 
updated Bethesda Criteria delineates situations where MSI testing should be carried out which 
include (I) individuals diagnosed with colorectal cancer under the age of 50, (II) individuals with 
metachronous or synchronous HNPCC-related cancers, (III) those whose colorectal tumors 
display histology associated with microsatellite instability and are under the age of 60, (IV) 
individuals with colorectal cancer and a first degree relative with an HNPCC-associated cancer 
with the stipulation that one of the cancers were diagnosed prior to the age of 50, and (V) 
individuals with colorectal cancer that have two or more first or second degree relatives with an 
HNPCC-associated cancer. The guideline elaborates on tumor histology as the “presence of 
tumor infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, mucinous/signet-ring 
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differentiation, or medullary growth pattern” (Umar, Boland et al. 2004). Additionally, the 
guidelines indicate that a consensus with regards to age limits and tumor histology has not been 
met. Recent studies suggest that the revised Bethesda Criteria have a sensitivity of 73-91% and 
an improved specificity of 77-82% (Palomaki, McClain et al. 2009). 
In 2009, the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) 
group has recommended that all individuals with colorectal cancer be screened for Lynch 
syndrome (EGAPP 2009). Additionally, the same group has endorsed testing of women with 
endometrial cancer diagnosed under the age of 50, with some centers testing all endometrial 
cancers.  
2.5 TESTING FOR MICROSATELLITE INSTABILITY 
Microsatellite testing has been praised and scrutinized for its use in identifying HNPCC 
individuals. The benefits of MSI testing are its reproducibility and that it can be carried out on 
small amounts of tissues (Zhang 2008). This is an important factor as MSI testing can be easily 
carried out on biopsies obtained during colonoscopies, where abnormal test results may play a 
role on future surgical decision.  
Additionally, extensive research has been performed on determining the ideal markers for 
MSI testing. Since the most common microsatellites are mononucleotide and dinucleotide 
repeats, markers for these sequences have been investigated. Mononucleotides were evaluated 
for MSI testing and two markers were valued for their microsatellite instability sensitivity. 
Mononucleotide markers Bat25 and Bat26 were supported for MSI testing as a result of studies 
indicating that all tested colorectal tumors displayed instability at the two loci (Loukola, Eklin et 
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al. 2001). An additional benefit of using the monomorphic Bat25 and Bat26 markers, is their 
ability to detect instability in the absence of normal tissue in non-African populations (Zhou, 
Hoang et al. 1998; Vilar and Gruber 2010). Therefore, biopsies of abnormal tissue can be 
collected without associated normal tissue for comparison. However, the increased prevalence of 
polymorphisms at the Bat26 loci in the African population, and rare frequency in other 
populations, emphasizes the benefit of DNA comparison to normal tissue in order to validate 
results (Loukola, Eklin et al. 2001). Nonetheless, additional testing is typically not recommended 
if there is an absence of instability in the tumor DNA. Similarly, researchers have investigated 
the use of dinucleotide markers and their efficacy of identifying microsatellite instability. Data 
indicates that tumors with MSI-L phenotypes typically show instability for dinucleotide markers, 
therefore it was determined that testing using only dinucleotide markers could lead to 
misclassification of tumors (Vilar and Gruber 2010).  
Originally, a lack of procedural standards resulted in a number of markers being used in 
order to determine instability. MSI-High had been defined as instability in >30% of loci, while 
MSI-Low is designated when 10-30% are unstable, and instability in <10% of loci is considered 
microsatellite stable (MSS). As a result of the variability in MSI protocol, guidelines were 
constructed to provide uniformity for testing purposes. The Bethesda guidelines recommend the 
utilization of a 5-marker panel, which includes two mononucleotides, Bat25 and Bat26, and three 
dinucleotides, D5s346, D2s123 and D17s250, (Loukola, Eklin et al. 2001; Vilar and Gruber 
2010). MSI-H histology was defined as the presence of instability in two or more markers, while 
MSI-L was classified as instability in only one marker (Boland, Thibodeau et al. 1998). 
Additionally, tumors that display instability at only dinucleotide markers are recommended to 
undergo testing with additional mononucleotide markers (Bedeir and Krasinskas 2011). The 
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marker panel continues to be under investigation with some groups suggesting the inclusion of 
additional mononucleotide markers to increase sensitivity, however, revisions to the Bethesda 
Guidelines have yet to be made (Umar, Boland et al. 2004). 
 
 
2.5.1 Limitations of MSI Testing 
Tumors tested for the purposes of identifying Lynch syndrome individuals inherently have 
limitations. As with many tests, sensitivity for MSI testing is not 100%, therefore, the potential 
for missing microsatellite instability is a plausible shortcoming. As the marker panel continues to 
be investigated, future revisions may result in an increased sensitivity for MSI testing. 
As previously noted, microsatellite instability is not exclusive to HNPCC tumors and is 
observed in sporadic neoplasms, serrated adenomas and individuals with hyperplastic polyposis 
syndrome (Hawkins and Ward 2001). As colorectal cancer is common in the general population, 
there is potential for the cancer to be of sporadic nature, representing a phenocopy of an HNPCC 
individual, and tumor testing in one individual may not be indicative of the risk within the family 
(de la Chapelle and Hampel 2010). Additionally, not all HNPCC tumors display MSI histology. 
It has been well established that tumors with MSH6 mutations are complicated in part by the 
variety of tumor phenotypes associated with them including MSI-H, MSI-L and MSS stable 
phenotypes, which can result in the omission of HNPCC individuals (Umar, Boland et al. 2004). 
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2.5.2 Other Applications of MSI Testing 
There are additional advantages for MSI testing in colon tumors besides identification of 
HNPCC individuals, including information on prognosis and treatment. MSI tumors typically 
have better prognoses and implications for response to chemotherapeutic drugs. The enhanced 
prognosis was based on the decreased likelihood of the cancer spreading to lymph nodes 
(Watanabe, Wu et al. 2001). With regards to treatment, some literature suggests that individuals 
with MSI tumors have superior response to 5-FU. However, other reports indicate that 
individuals with stage II or stage III MSI tumors do not benefit from FU-based adjuvant therapy 
compared to those with similar staging with MSS or MSI-L tumors (Ribic, Sargent et al. 2003; 
de la Chapelle and Hampel 2010). Additionally, studies indicate that survival and recurrence-free 
survival do not significantly differ whether or not treated with FU-based chemotherapy in 
individuals with MSI-H tumors  (Des Guetz, Schischmanoff et al. 2009). This data supports that 
stage II and stage III MSI positive individuals should not be subjected to hazardous 
chemotherapy treatment, opposed to the current standard of practice (de la Chapelle and Hampel 
2010). Although MSI tumor response to 5-FU has been widely debated, studies on the efficacy 
of irinotecan on MSI tumors have been encouraging, but are still in their infancy (Vilar and 
Gruber 2010). 
For these reasons, implementing MSI testing as a standard of practice can have an impact 
on hereditary cancer screening, therapy and as a prognostic indicator for patients (Vilar and 
Gruber 2010).   
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2.6 IMMUNOHISTOCHEMISTRY 
The limitations of MSI testing have prompted investigations for alternative tumor tests. The most 
successful alternative test for the purposes of identifying HNPCC individuals is 
immunohistochemistry (IHC), therefore this protocol was proposed as substitute to MSI testing. 
Immunohistochemistry utilizes monoclonal anti-bodies against the four mismatch repair genes 
associated with HNPCC, the presence of which is represented by positive staining. 
Immunohistochemistry detects a mutation resulting in a deficiency MMR protein by the absence 
of staining in the tumor tissue. Additionally, the lack of expression of a protein corresponds to 
their dependence as heterodimers, where the degradation of MLH1 or MSH2 protein results in 
the concurrent loss of its partner protein. Alternatively abnormalities in MSH6 and PMS2 result 
in a loss of staining for only those proteins, due to the alternative binding capability of MLH1 
and MSH2. Some MLH1 mutations that are antigenically active show only a loss of PMS2 (Shia 
2008). Nonetheless, the heterodimerization staining pattern concept has lead to the proposition of 
transitioning to a two-antibody system, of MSH6 and PMS2, which would reduce the costs of 
testing. The model is founded on the principle that abnormal IHC testing of MSH6 or PMS2 
would prompt reflex testing of the heterodimer partner in order to determine which protein is 
affected, helping to target gene testing to a single genes. The Bethesda Criteria were constructed 
for the purposes of outlining situations where MSI testing should occur, and not IHC. However, 
it has been suggested that the recommendations be expanded to include IHC testing (Lenz 2005). 
There are several benefits of IHC testing. Proponents of IHC indicate that testing can be 
done at the time of surgery, identifying the prospective MMR gene, decreasing the need for 
postoperative genetic service providers to test archived tumor tissue. Another benefit of IHC is 
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its wide availability, as it does not need to be performed in a molecular diagnostic laboratory, but 
in more prevalent pathology laboratories (Hampel, Frankel et al. 2008). 
2.6.1 Limitations of IHC 
In the interest of uncovering the most efficacious testing for identifying HNPCC, the limitations 
of IHC testing have been evaluated and its shortcomings identified. Proteins that remain 
antigenically intact but carry mutations that result in a loss of protein function pose a significant 
problem when IHC is carried out independently, as they stain positively on testing. The result 
has been documented to occur in various MLH1 and MSH2 mutations including missense, 
truncating and large in-frame deletions. Similarly, antigenically stable somatic changes in the 
wild-type allele may produce positive staining within the analyzed tumor tissue and distort 
interpretation of IHC testing. Another limitation of IHC is the difficulty interpreting the variation 
in staining patterns. Due to the nature of the procedure, immunohistochemistry is prone to weak, 
focal, and ambiguous staining, leading to indefinite results or the requirement of additional 
testing (Shia 2008). IHC is also susceptible to poor staining if the obtained biopsies are small, 
which becomes problematic in situations where decisions on medical management need to be 
made prior to surgery. Additionally, as opposed to the Bethesda Criteria for MSI testing, a 
standard of procedure for IHC testing is lacking. Variations in the laboratory fixatives, tissue 
handling protocols, and processing methods for IHC testing pose a potential risk of discrepancy 
in result evaluation (Umar, Boland et al. 2004; Shia 2008).  
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2.7 MSI VERSUS IHC 
The shortcomings of both MSI and IHC testing have sparked great debate regarding the ideal test 
to identify germline mutations in MMR genes. Comparisons of each test type have been 
explicitly carried out to evaluate efficacy of HNPCC identification. Studies indicate that when 
MLH1 and MSH2 staining was performed, abnormal results were obtained in 85% of the known 
mutation carriers, and another study suggests IHC to have specificity of 95% with regards to 
MLH1 and MSH2 mutations (Shia, Klimstra et al. 2005). However, when four MMR antibodies 
were included in the IHC testing, the sensitivity improved to 92% as the addition of the PMS2 
antibody was able to detect MLH1 mutations that were initially missed by IHC (Shia 2008).  
In comparison, approximately 93% of mutation carriers had microsatellite instability 
detected on their tumors (Shia 2008). Further corroborating the detection ability of MSI testing, 
one study indicated that all MLH1 or MSH2 negative tumors displayed microsatellite instability 
(Lindor, Burgart et al. 2002). As previously discussed, due to the heterogeneity in microsatellite 
instability phenotype observed in MSH6 absent tumors, MSI testing was not as efficient in 
detecting MSH6 mutation carriers compared to IHC.  
Reviewers indicate that IHC and MSI testing are not equivalent tests as evidence supports 
that both tests are able to detect cases that the other cannot (Shia, Ellis et al. 2004). Therefore, 
although carrying out both types of testing is not the most cost-effective method, it is certainly 
the most sensitive.   
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2.8 BETHESDA CRITERIA AND TUMOR TESTING 
The current Bethesda criteria are guidelines for MSI testing for colorectal tumors only, however 
the use of MSI and IHC in extracolonic tissue has also been assessed.  
Microsatellite instability has also been observed in extracolonic tumor and attempts to 
quantify the prevalence and association with HNPCC have been carried out. Similar to colorectal 
cancer, approximately 9% of women with endometrial cancer diagnosed younger than 50 years 
of age have an MMR mutation, however, it has been reported that nearly half of women with 
Lynch syndrome are diagnosed beyond that threshold (Lu, Schorge et al. 2007; Kwon, Scott et 
al. 2011). Paralleling increased rate of tumor development from MSI adenomas in colon cancers 
cases, studies investigating endometrial cancer indicate that MSI has been detected in complex 
atypical hyperplasia associated with uterine endometrioid carcinoma, while MSI was absent in 
atypical tissue not associated with endometrial carcinoma (Esteller, Levine et al. 1998). 
However, it has been documented that complex atypical hyperplasia is only present in small 
amounts on biopsies, making testing for MSI difficult. Additionally, microsatellite instability due 
to altered protein expression from MMR germline mutations may develop over time and for that 
reason instability may not be detectable when endometrial tissue is obtained (Staebler, Lax et al. 
2000). Therefore, it has been suggested that IHC testing may be a more appropriate method for 
analysis of endometrial tissue over MSI testing. Microsatellite instability is also observed in 20-
25% of sporadic uterine endometrioid cancer, the most common form of endometrial cancer 
(Staebler, Lax et al. 2000). Similar to the methylation of MLH1 observed in sporadic colorectal 
cancer, studies have revealed that correlations to MLH1 silencing by epigenetic factors also 
described in a significant number of sporadic endometrial cancers (Esteller, Levine et al. 1998). 
When evaluating MSI in gastric tumors, MSI was observed in approximately 13-44% of gastric 
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carcinomas, with the Bat26 marker being the most sensitive marker in identifying instability 
(Wirtz, Muller et al. 1998; Halling, Harper et al. 1999).  
Literature summarizing MSI testing on extracolonic cancer tissue indicates that although 
MSI and IHC testing in these tissues have revealed similar characteristics, the sensitivity and 
specificity of testing extracolonic cancers has not been well established. Furthermore, the 
markers recommended for MSI are specific to colorectal cancer, therefore, MSI testing of 
extracolonic cancers using the same marker panel may not display the same pattern, resulting in 
inaccurate result interpretations (Kuismanen, Moisio et al. 2002; Weissman, Bellcross et al. 
2011).  
It has been debated whether polyps are a viable option for MSI and IHC testing. Polyps 
have been shown to be sensitive to the mutator effect, therefore, as precancerous lesions, they are 
potential candidates for testing. Additionally, studies suggest that the polyps in individuals with 
Lynch syndrome develop into cancer at a much higher rate (1-3 years from detection) compared 
to the general population (8-17 years). Therefore, identifying HNPCC individuals prior to tumor 
development would significantly reduce morbidity and mortality (Jass and Stewart 1992; Vasen, 
Nagengast et al. 1995).  
One study suggested that 88% of large (>5mm) and proximal adenomas in HNPCC 
individuals display loss of expression of an MMR protein. However, it was concluded that IHC 
testing could be carried out on adenomas in cases suspicious for HNPCC, with the caveat that 
intact staining of MMR proteins could not exclude HNPCC due to the poor sensitivity 
(Halvarsson, Lindblom et al. 2005) 
Originally, the Bethesda criteria recommended individuals under the age of 40 that were 
found to have adenomas should undergo MSI testing. This recommendation was supported by 
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studies showing the detection of MSI in adenomas resulting in the identification of individuals 
with Lynch Syndrome (Loukola, Salovaara et al. 1999). However, additional studies revealed 
that the scarcity of appropriate tissue in polyps lead to a lack of yield for MSI testing, resulting in 
the removal of the recommendation in the subsequent Bethesda Criteria revision (Jass, Pokos et 
al. 1996; Umar, Boland et al. 2004; Velayos, Allen et al. 2005). However, the International 
Collaborative group has defined features of adenomas of which clinicians and pathologists 
should be cognizant including: early age of onset, relatively low number of adenomas, an 
increased proportion with a villous growth pattern, a high degree of dysplasia, and their rapid 
development to carcinoma (Vasen, Watson et al. 1999). 
2.9 GENETIC INFORMATION AND TUMOR TESTING 
Many investigators consider microsatellite testing to be a genetic test (based on its direct 
assessment of DNA motifs) and, thus, it requires a patient’s informed consent. Others contest 
that microsatellite testing does not elicit information on the patient’s inherited risks or the risks 
of their family members, and avoids potential for psychosocial or psychological harm that is 
often associated with genetic tests. Furthermore, MSI testing is performed on cancerous tissue, 
which may not be indicative of an individual’s germline. Some researchers suggested that 
microsatellite testing on tumors is similar to estrogen receptor testing in breast cancer patients, 
which does not require informed consent (Chubak, Heald et al. 2011). Similarly, researchers 
suggest that IHC is a test of tumor phenotype and should not be regarded as a genetic test. 
However, IHC testing has the ability to identify specific MMR genes that are dysfunctional, 
potentially providing information about the individual’s genetic makeup, as well as the genetics 
 33 
of his or her family members (Chubak, Heald et al. 2011). This result has been corroborated by 
reports that loss of MSH2, MSH6 and PMS2 protein is exclusive to HNPCC individuals (Abdel-
Rahman, Mecklin et al. 2006; Lagerstedt Robinson, Liu et al. 2007). As a result, 
immunohistochemistry has a greater potential for psychosocial risk for patients and their 
families. 
Guidelines are available for the performance of genetic tests. The American Society of 
Clinical Oncology policy indicates that genetic testing should be carried out collectively with 
pre- and post-test counseling in order to ensure the patient’s comprehension of the risks and 
benefits of the testing (ASCO 2003). Additionally, the Evaluation of Genomic Applications in 
Practice and Prevention (EGAPP) group states that informed consent should be obtained prior to 
MSI or IHC testing (EGAPP 2009).  
2.10 GENETIC TESTING FOR HNPCC 
Genetic testing for at-risk individuals can be initiated in several different ways. Individuals that 
were identified to be at risk for HNPCC as a result of abnormal MSI and/or IHC testing may 
undergo genetic testing. Lack of MMR staining on IHC can indicate the specific MMR gene to 
test first. Reflex testing of the heterodimerizing protein partner can occur in cases where a 
mutation is not detected in the primary gene candidate. As EPCAM mutations can account for a 
loss of expression in MSH2, reflex testing of the gene can be considered when germline 
mutations are not identified in MSH2/MSH6 absent tumors.  
Individuals may still be considered for a clinical diagnosis of Lynch Syndrome if (1) they  
test negative for a germline mutation but their tumor displays microsatellite instability, exhibits a 
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loss of expression of an MMR protein on IHC testing and, in MLH1 cases, lack a BRAF 
mutation. As mutations may be undetectable with current technology, these individuals and at-
risk family members should undergo screening as recommended for Lynch syndrome 
individuals.  
Unaffected individuals whose family history meets the Amsterdam criteria are often 
referred for genetic testing of the most commonly mutated MMR genes, MLH1 and MSH2. 
Tumor testing of family members with an HNPCC cancer is beneficial for targeted genetic 
evaluation of the proband. If tissue is unattainable, the next most prudent step is germline testing 
of a family member affected with an HNPCC associated cancer, ideally with the youngest age of 
onset. If there are no eligible individuals diagnosed with an HNPCC cancer in a family 
suspicious for the syndrome, genetic testing on another family member can be considered with 
the caveat that there is a significantly lower chance to obtain an informative test result. However, 
most individuals are not identified in clinics based on family history alone. Many individuals are 
referred for genetic counseling based on abnormal tissue tumor test results. When test results 
indicate a risk of HNPCC, referral to a genetics clinic is warranted. Genetic consults can help 
educate patients on test implications and address other psychosocial issues.  
2.10.1 Mutations  
There have been over 200 mutations identified in MLH1, over 170 mutations in MSH2 and over 
30 mutations in MSH6 (Peltomaki and Vasen 2004). Large deletions and rearrangements are 
responsible for approximately 20% of mutations in the MSH2 and PMS2 genes, and deletions 
account or 5-10% of MLH1 and MSH6 mutations (Wijnen, van der Klift et al. 1998; 
Charbonnier, Raux et al. 2000; Senter, Clendenning et al. 2008). Due to the array of mutations, 
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testing mutations in MMR genes incorporates sequence analysis and methods for detecting gene 
deletions, duplications and rearrangements. 
The majority of MSH2 mutations are protein truncating (Salahshor, Koelble et al. 2001; 
Wahlberg, Schmeits et al. 2002). However, more than 1/3 of MLH1 mutations and approximately 
24% of all mutations identified in Lynch syndrome individuals are missense mutations 
(Peltomaki and Vasen 2004). Missense mutations can be difficult to assess as benign 
polymorphisms or deleterious mutations, with the classifications having significantly different 
medical management recommendations (Weissman, Bellcross et al. 2011). Data suggests that 
individuals with a personal history of cancer who received uninformative genetic test results had 
similar distress levels to mutation carriers, supporting the need for follow-up discussion or 
additional counseling so as to ensure these individuals full comprehend their results (Gritz, 
Peterson et al. 2005).  
2.10.2 Testing Sensitivity 
Palomaki and McClain indicate an estimate of greater than 90% for the sensitivity of MLH1, 
MSH2, and MSH6 mutation detection, however, many labs cite a sensitivity of greater than 98% 
(Palomaki, McClain et al. 2009). Reasons for the inability to detect all mutations include 
improper specimen handling, unanticipated molecular reactions, as well as data analysis and 
computational errors.  Balanced genomic rearrangements may also attribute to reduced 
sensitivity of genetic testing. Other observed mutations, such as large deletions and splice site 
mutations, prove difficult to identify in MSH2 (Wijnen, van der Klift et al. 1998; Nakagawa, Yan 
et al. 2002). 
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Initially, PMS2 proved to be a difficult for mutation testing due to the presence of 
numerous pseudogenes. However, with the advent of long range PCR, the testing sensitivity has 
improved with the exception of exons 13-15, where pseudogenes may still interfere with testing 
accuracy. Currently, more than 60% of individuals with PMS2-absent IHC results have been 
found to possess germline mutations (Senter, Clendenning et al. 2008). 
2.10.3 Test Results 
Identification of a germline mutation in an MMR gene is interpreted as diagnostic for Lynch 
Syndrome. The result allows at-risk family members to undergo single-site genetic testing for the 
mutation in order to definitively determine their mutation status. Subsequent, positive results in 
family members infer an increased risk for HNPCC associated cancers, while a negative result 
assumes the mutation was not inherited and risk values lower to that of the general population. 
Probands whose parents test negative for mutations should be counseled for de novo mutations. 
Literature reveals that de novo mutations in MMR genes are observed in 1-5% of cases, much 
more rare in HNPCC compared to other CRC cancer syndromes (Win, Jenkins et al. 2011). 
However, health care providers may also consider other issues, such as non-paternity.  
Negative genetic test results are more difficult to assess as reduced testing sensitivity or 
testing an individual who developed a sporadic cancer within a HNPCC family can lead to 
inaccurate test result interpretation. Consequently, as genetic testing sensitivity for the MMR 
genes has developed, a wide spectrum of genetic alterations has been obtained.  
There are several benefits for at-risk family members who choose to undergo genetic 
testing. Firstly, they need only carry out single-site mutation for the identified mutation, and 
predictive single-site genetic testing is less costly than full sequence analysis. Secondly, 
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compared to numerous outcomes and implications of full mutation sequencing, result 
interpretation of single-site testing is relatively unambiguous. 
2.11 PUBLIC HEALTH RELEVANCE 
Colon cancer is the 4th most commonly diagnosed cancer in the United States and HNPCC has 
been documented to be responsible for 2-5% of all colorectal cancers (Lynch and de la Chapelle 
2003; de la Chapelle 2004; Senter, Clendenning et al. 2008). Additionally, endometrial cancer is 
the fourth most common cancer observed in North American women and HNPCC, the most 
common hereditary endometrial cancer syndrome, accounts for 1-4% of all endometrial cancers 
(Hampel, Frankel et al. 2005). 
The prevalence of MMR mutations in the general population is approximately 1 in 2700, 
however, it has been documented to be as high as 1 in 360-440 (Chen, Wang et al. 2006; Hampel 
and de la Chapelle 2011; Win, Jenkins et al. 2011). Despite its prevalence, impact on individual 
morbidity and burden on the health care system, Lynch Syndrome remains clinically under 
diagnosed (Singh, Schiesser et al. 2010). 
Individuals with hereditary cancer syndrome develop cancers at a younger age, leading to 
a greater loss of years of life. Identifying those diagnosed with Lynch Syndrome is important as 
these individuals are at an increased risk for metachronous and synchronous cancers. Several 
auxiliary medical management options would be available to these individuals including early 
detection through cancer screening and risk reduction procedures. Furthermore, identifying these 
individuals could lead to counseling of unaffected, at-risk family members, who would also be 
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offered supplemental medical management opportunities. Family members who do not carry an 
MMR mutation are reprieved from increased screening and surgery. 
 
2.12 SCREENING AND PREVENTION IN HNPCC INDIVIDUALS 
 
Increased cancer surveillance and prophylactic surgery have decreased mortality and morbidity 
in HNPCC individuals (Renkonen-Sinisalo, Aarnio et al. 2000; Schmeler, Lynch et al. 2006). 
Both unaffected and affected HNPCC individuals can benefit from colon cancer screening 
through colonoscopies. HNPCC colorectal cancers have been shown to derive from adenomas 
and develop into cancer earlier and more rapidly when compared to sporadic cancer (Ahnen 
2011). Therefore, early and more frequent colonoscopies are beneficial for the removal of 
precancerous lesions prior to their development to cancer, or for detecting cancers at a less 
advanced stage.  As a result, studies indicate that cancer surveillance in unaffected HNPCC 
individuals reduce mortality and morbidity by 65% over a period of 15 years (Jarvinen, Aarnio et 
al. 2000), Studies indicate that colonoscopies reduce the risk of metachronous colon cancers in 
affected HNPCC individuals as well (Jarvinen, Aarnio et al. 2000). Colonoscopies in HNPCC 
patients are cost effective, and it is recommended that these individuals undergo earlier and more 
frequent screening compared to the general population (Vasen, van Ballegooijen et al. 1998). 
The current guidelines by the National Comprehensive Cancer Network for colon cancer 
screening in Lynch syndrome individuals recommends that colonoscopies be initiated between 
the ages of 20-25 at a frequency of every 1-2 years. The guidelines indicate that if there is a 
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family history of colon cancer diagnosed prior to the age of 25 screening should occur 2-5 years 
prior to the age of diagnosis (NCCN 2010)1. 
Hereditary colorectal cancers are managed and treated differently than sporadic tumors. 
More extensive surgeries may be recommended for HNPCC individuals because of the increased 
risk for secondary colorectal cancer development (Vasen 2000). However, the decision should be 
balanced against the treatment’s impact on quality of life (Chen, Chiang et al. 2008). The current 
guidelines by the National Comprehensive Cancer Network indicate that HNPCC individuals 
that are not amenable to screening or non-compliant to recommendations can consider subtotal 
colectomy. HNPCC individuals with unresectable adenomas or high-grade dysplasia are 
recommended to undergo ileorectal anastomosis, during which the surgeons perform a total 
colectomy and connect the ileum to the rectum (NCCN 2010).  
Gynecological screening in Lynch syndrome individuals has the capability of identifying 
pre-malignant lesions, but debates remain regarding its effect on mortality and the appropriate 
time intervals between sampling (Auranen and Joutsiniemi 2011). The difficulty in screening for 
endometrial cancer in women with Lynch syndrome is the lack of understanding surrounding its 
development. As not all Lynch syndrome endometrial cancers develop from hyperplasia, and 
sampling does not detect all cases of hyperplasia, endometrial sampling can fail to detect many 
cancers and hyperplasia (Auranen and Joutsiniemi 2011). Additionally, endometrial sampling is 
an invasive procedure and can be painful, leading to reduced compliance; current 
recommendations should be broached during discussion of medical management in order to 
                                                 
1Cited with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(tm)) for [GUIDELINE NAME]  V[GUIDELINE VERSION 
NUMBER](c) 2011 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines(tm) and illustrations herein may not be reproduced in any form for 
any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. NATIONAL 
COMPREHENSIVE CANCER NETWORK(r), NCCN(r), NCCN GUIDELINES(tm), and all other NCCN Content are trademarks owned by the National Comprehensive Cancer 
Network, Inc. 
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increase effectiveness. A meta-analysis study by Auranen and Joutsiniemi indicates that there is 
a lack of evidence regarding the benefit of gynecological cancer screening to serve as the 
foundation of clinical recommendations for Lynch syndrome patients (Auranen and Joutsiniemi 
2011). As a result, the National Comprehensive Cancer Network’s current recommendations for 
gynecological cancer screening indicate that HNPCC women can consider transvaginal 
ultrasound for endometrial and ovarian cancer. The guidelines indicate that endometrial sampling 
may be helpful in some cases, however, all women should be educated regarding endometrial 
cancer, associated symptoms, and management (NCCN 2010). 
Another available option for women with HNPCC include prophylactic surgeries to 
reduce the risk of tumor development. Prophylactic hysterectomy and bilateral salpingo-
oophorectomy (BSO) reduces the risk of ovarian and endometrial cancer in women with 
HNPCC. The decision to have prophylactic surgery is complex and personal, and women should 
be well informed on several important aspects. Discussions with family members, gynecologists, 
oncologists, additional health care providers, or other women from HNPCC families may aid a 
woman with the decision process of prophylactic surgery. Issues to consider that can influence a 
woman’s decision include the risks of the procedure such as loss of fertility and the ensuing 
onset and management of menopause. Comparisons between gynecological screening and 
prophylactic surgery have been assessed to determine the effectiveness at an individual and 
population level. There is evidence that prophylactic TAH-BSO results in longer life expectancy, 
higher number of quality-adjusted life-years and is the most cost-effective option when 
compared to those undergoing gynecological examinations and surveillance for Lynch Syndrome 
(Chen, Yang et al. 2007; Yang, Caughey et al. 2011). The study suggests that the underpinning 
of the benefit of prophylactic surgery is derived from the increased probability for cancer 
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diagnosis for those who opt for exams and surveillance, as well as the associated treatment costs 
of continuous surveillance. Many women choose to pursue surveillance until time of 
prophylactic surgery, conclusion of childbearing or onset of menopause. However, studies 
suggest that women should undergo prophylactic surgery as early as possible for greatest risk 
reduction and cost-effectiveness purposes (Chen, Yang et al. 2007; Yang, Caughey et al. 2011). 
The National Comprehensive Cancer Network current recommendations for gynecological 
prophylactic surgery for HNPCC women indicate that women who have completed childbearing 
can consider prophylactic hysterectomy and bilateral salpingo-oophorectomy (NCCN 2010). 
Patients and clinicians should also be aware of the continued cancer risks even after 
treatment of cancer and 5-year survival period. Lynch syndrome women who survive a 
gynecological cancer still have the same inherent risk for colorectal cancer as they had 
previously. Their understanding of this perpetual risk may play a role in their decision to undergo 
simultaneous prophylactic gynecological and colon surgeries (Yang, Caughey et al. 2011). 
Additionally, HNPCC individuals should consider screening for other HNPCC-associated 
cancers. The National Comprehensive Cancer Network recommendations indicate that HNPCC 
individuals should undergo Esophagogastroduodenoscopy (EGD) for gastric cancer screening, 
initiating at the age of 30-35 with follow-up every 2-3 years. Similarly, HNPCC individuals 
should also consider upper gastrointestinal endoscopy or capsule endoscopy for small bowel 
cancer at the same age and interval. An annual physical examination and urinalysis may also be 
considered to detect urothelial and central nervous system cancers (NCCN 2010).  
Preventative therapies for colorectal cancer have also been investigated. Research 
indicates that the consumption of NSAID as a chemoprevention method for colorectal cancer 
may reduce the risk for individuals to develop polyps. However, chemoprevention medication’s 
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effect on individuals with HNPCC appears dissimilar. Studies on chemoprevention of colorectal 
cancer in Lynch syndrome individuals revealed an absence of a significant reduction in the 
incidence of adenomas or cancer in these individuals. However, it does not rule out the 
possibility of minor reductions in risk (Lindor, Petersen et al. 2006; Burn, Bishop et al. 2008). 
2.12.1 Screening in Familial Colorectal Cancer Type X 
Failure to identify a germline mutation in individuals at risk of HNPCC can result from reduced 
testing sensitivity, epigenetic factors or an absence of a mutation. In these cases, medical 
management is unclear, but the presence or absence of a strong family history should be 
incorporated into recommendations for the patient. 
Approximately 50-60% of individuals meeting the Amsterdam I Criteria have a germline 
mutation identified in MLH1 or MSH2 (Syngal, Fox et al. 2000; Lindor, Petersen et al. 2006). 
Families that meet the Amsterdam I Criteria without an identified mutation are referred to as 
familial colorectal cancer type X. Data indicates that familial colorectal cancer type X 
individuals are at an increased risk for colorectal cancer compared to the general population. The 
guidelines regarding surveillance in familial colorectal cancer type X individuals are not well 
defined. Recommendations for increased surveillance, that are less aggressive than those with 
HNPCC, may be appropriate (Lindor, Rabe et al. 2005; Lindor, Petersen et al. 2006). Familial 
colorectal cancer type X at-risk family members should also be considered for increased 
screening. Studies indicate there is no significant evidence to suggest an increased risk for 
extracolonic cancers, and increased screening for these cancers is not recommended. However, it 
has been noted that since Amsterdam I Criteria only accounts for families with colorectal 
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cancers, extracolonic cancer risks of familial colorectal cancer type X family members may not 
be representative (Lynch and de la Chapelle 2003).  
 
2.12.2 Future Treatment 
With the increasing knowledge of genomics and its role in tumor development, continuous 
progress on treatment methods has unfolded. Similar to genomic-centered therapies seen in 
BRCA mutation carriers, in whom PARP-1 inhibitors are used to induce cellular lethality in 
tumors, MSI tumors or MMR mutation carriers may be candidates for alternative treatment 
(Vilar and Gruber 2010). Additionally, drug development based on molecular subtypes is a 
burgeoning field in cancer treatment and may soon have implications for HNPCC individuals. 
2.13 IMPLICATIONS FOR FAMILY MEMBERS 
It is apparent that the implications for individuals with HNPCC are considerable and identifying 
this high-risk group is a significant public health issue. The importance of identifying affected 
individuals with HNPCC is not only vital for the patient, but also for at-risk family members. If 
an MMR mutation has been identified in the family, relatives may choose to undergo genetic 
testing to determine their personal cancer risks. One study indicated that 75% of individuals 
meeting a clinical diagnosis of HNPCC or who underwent genetic testing for HNPCC, 
encouraged family members to undergo medical assessments (Ishii, Arai et al. 2011). The study 
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illustrates the impact that probands may have on at-risk family members seeking medical 
consultation, further accentuating the significance of identifying HNPCC individuals.  
As HNPCC is an autosomal dominant condition, probands’ siblings and children have a 
50% risk for also carrying a deleterious MMR mutation. Additionally, identification of a 
mutation in a proband also infers that a parent is an obligate carrier. Anxiety and guilt are 
emotions observed in families with genetic cancer conditions and need to be addressed 
appropriately by health care providers. Identifying MMR mutations in families may also provide 
an explanation in families struggling to understand the overwhelming number of cancers in the 
family.  
Identifying HNPCC individuals may also have implications for family planning. Prenatal 
genetic testing is a service typically offered as a screen for childhood conditions that are 
associated with severe health implications such as Cystic Fibrosis and Tay-Sachs (Strom, 
Ginsberg et al. 1998). However, prenatal genetic evaluation for highly penetrant, familial cancer 
syndromes has been investigated (Dewanwala, Chittenden et al. 2011). Preimplantation genetic 
diagnosis has been carried out on conditions such as Li-Fraumeni Syndrome (LFS), 
Neurofibromatosis (NF), Hereditary Breast and Ovarian cancer syndrome (HBOC), Familial 
Adenomatous Polyposis (FAP), Von-Hippel Lindau (VHL) and Lynch Syndrome (Offit, Sagi et 
al. 2006). However, the American Medical Association indicates that prenatal testing is most 
appropriate “for women or couples whose medical histories or family backgrounds indicate an 
elevated risk of fetal genetic disorder” (Association 1994). Nonetheless, a recent study indicated 
that 42% of Lynch syndrome patients would consider prenatal diagnostic testing in future 
pregnancies (Dewanwala, Chittenden et al. 2011). While the sample size is not large, this study 
also revealed the affect of Lynch Syndrome genetic testing on family planning (Dewanwala, 
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Chittenden et al. 2011). Approximately 20% of women with Lynch syndrome would consider 
childbearing at younger ages in order to pursue prophylactic surgery at an earlier age 
(Dewanwala, Chittenden et al. 2011). The study further suggested that health care providers 
should be aware of the availability of prenatal testing for Lynch Syndrome, be able to discuss 
testing options prior to or during pregnancy, or make appropriate referrals in order to provide the 
best care possible to these individuals. 
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3.0  STUDY AIMS 
Aim 1: A quality control analysis of the genetic counseling attendance for at-risk HNPCC 
patients and potential contributing factors. 
 
Aim 2: Assessment of the quality of patient family history documentation for the purposes of 
Bethesda Criteria classification compared to family history obtained from medical record review. 
 
Aim 3: Evaluate the impact of family history, pathological and surgical factors in identifying 
individuals meeting the Bethesda Criteria. 
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4.0  METHODS 
Using a research protocol approved by University of Pittsburgh International Review Board 
(IRB0408094), participants were consented into the research study. Additionally, blinded data on 
patients undergoing MSI/IHC testing, those with colorectal cancer under the age of 50, and those 
seeing a genetic counselor in the UPMC system were also provided for study purposes. In total, 
589 participants who were seen by UPMC genetic counselors, gastroenterologists or oncologists 
as a result of cancer diagnosis, polyps or family history, or attended the UPMC colorectal cancer 
high-risk clinic, or underwent MSI or IHC testing at UPMC between 2004-2009 were selected 
for the study. This time frame was selected to reflect a consistent protocol period between the 
revision of the Bethesda Criteria in 2004 and the EGAPP statement regarding testing of all colon 
cancer in 2009. 
Participants meetings either the Bethesda criteria, Amsterdam I or Amsterdam II Criteria 
were selected for further evaluation. The rationale for MSI/IHC testing was determined by 
medical documentation review and classified by the researcher. Bethesda Criteria classification 
was based on medical documentation for MSI or IHC testing of the individual at the time of 
testing. Researchers completed secondary Bethesda Criteria classification if medical 
documentation revealed additional criteria met. Concurrent pathological and family history 
criteria were classified by priority given to the criterion leading to testing if this could be 
assessed chronologically.  
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 Blinded surgical, pathological and medical records, patient history documentation, and 
physician or genetic counseling notes were reviewed to ascertain genetic test results, molecular 
tumor test results, tumor location, surgical history and personal and family cancer history. 
Individuals that underwent MSI/IHC testing on physicians’ request due to strong family history 
or suspicion of Lynch syndrome, but did not meet Bethesda Criteria, were also evaluated. 
Families with known polyposis syndromes were excluded from data analysis as per the 
Amsterdam criteria. The Revised Bethesda criteria were interpreted so that only probands with 
colorectal cancer tumors were eligible for MSI/IHC testing. The fourth Bethesda Criteria was 
fulfilled if either the proband with colorectal cancer or their first-degree relative, with an 
HNPCC-related tumor, were diagnosed under the age of 50. Differentiation between Bethesda II 
criteria, metachronous and synchronous tumors, was attempted in each case in order to assess the 
impact of personal cancer history and surgical identification of patients. 
At-risk individuals included all individuals with abnormal microsatellite instability (MSI) 
or immunohistochemical (IHC) analysis of MMR proteins, including both those that met and 
those that did not meet the Bethesda Criteria. The genetic counseling referral process for at-risk 
HNPCC individuals was evaluated by comparing the total number if individuals with an 
abnormal MSI/IHC that attended with a genetic counselor to the entire at-risk population. 
Genetic counseling notes were used to verify individuals that attended with a counselor. 
Statistical analyses were performed to compare characteristics of individuals who did or did not 
meet with a genetic counselor. Contingency tables and Cochran-Armitage test was used to 
determine differences and trends in the subject cohorts.  
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5.0  RESULTS 
The total number of individuals who had IHC/MSI testing between 2004-2009 at UPMC and met 
one of the Bethesda Criteria was 389 (Table 1). Of the 389 individuals who met a Bethesda 
Criteria, a total of 79 (20.3%) patients obtained an abnormal MSI/IHC result; an additional 7 
individuals displayed absent MLH1 staining on IHC testing and subsequent testing revealed that 
they had a BRAF mutation.  
Eighteen individuals not meeting a Bethesda Criteria also had an abnormal MSI/IHC test 
result. Included in this group were individuals with endometrial cancer, polyps, other HNPCC 
associated cancer, as well as individuals with colorectal cancer that did not meet one of the 
Bethesda Criteria. The individuals in this subgroup were referred for MSI and IHC testing at the 
request of the treating practitioner based on suspicion for HNPCC. 
Of those 227 individuals classified as meeting Bethesda Criteria I, 6 (2.65%) did not 
undergo MSI/IHC testing. No information was provided to explain why these individuals were 
tested. Of the remaining 221 individuals with Bethesda Criteria I, 14% (31) had abnormal 
MSI/IHC result. 
 
 
 
 
 50 
Table 1. Individuals meeting Bethesda Criteria in the study population and their classification  
*BI: <50y ; BII: metachronous/synchronous HNPCC tumors ; BIII: tumor histology ; BIV: CRC with 1st 
degree relative with HNPCC tumor, one diagnosed <50y ; BV: CRC with ≥ 2 1st or 2nd degree relatives with 
HNPCC tumor 
 
Family history information was further assessed via medical record review (Table 2). In 
total, 60 individuals met additional personal or family history-based criteria, which were not 
identified upon initial consultation. 
 
 Table 2. Individuals that met additional personal and family history Bethesda Criteria 
 
Data in Table 3 and Table 4 display the number of individuals eligible for genetic 
counseling (abnormal MSI/IHC) who saw a genetic counselor and those who underwent genetic 
testing, respectively. Of 97 patients with abnormal MSI/IHC, 44 (45.3%) met with a genetic 
counselor. Within this subset of 44 patients, 37 (84%) also had genetic testing carried out. In this 
cohort, there was no significant difference between the proportion of women attending genetic 
counseling compared to men (OR = 2.33; 95% CI: 0.96, 5.49) . 
 BI BII BIII BIV BV AMS II Total 
Number of 
individuals 
227 
(58.5%) 
49 
(12.6%) 
84 
(21.6%) 
5 
(1.2%) 
18 
(4.6%) 
6 
(1.6%) 389 
 BII (metachronous) BIV BV AMS II 
No 
additional 
personal 
or family 
history 
Total # of 
individuals 
meeting 
another 
Bethesda 
Criteria 
BI individuals 6 (2.6%) 
25 
(11%) 
3 
(1.3%) 
11 
(4.8%) 
182 
(80.3%) 45 
BII individuals 0 2 (4%) 
1 
(2%) 
4 
(8%) 
42 
(86%) 7 
BIII individuals 3 (3.5%) 0 
5 
(5.9%) 0 
76 
(90.6%) 8 
Total 9 27 8 15 200 60 
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The most frequently reported reason for patients not undergoing genetic testing was a 
lack of insurance coverage or other financial limitations. Among the group that underwent 
genetic testing, testing identified 14 (37.8%) germline mutations, 6 (16.2%) variants of uncertain 
significance and 2  (5.4%) results were unknown.  The 14 germline mutations were contained in 
the following loci: MLH1 (5), MSH2 (7), and MSH6 (2). 
Table 3. Attendance of population with abnormal MSI/IHC results with a genetic counselor 
 
 
 
*GC = genetic counselor 
** Population includes both individuals meeting a Bethesda Criteria and those who did not 
 
Table 4. Genetic testing status of the population with abnormal MSI/IHC results who met with a counselor 
 
 
 
 
To investigate whether other factors might influence whether individuals attend a genetic 
counseling session, all individuals with abnormal MSI/IHC results and their personal and family 
history of cancer were assessed. In table 5, the Bethesda criteria cohort is further classified by 
age less than 50 years of age, pathological criteria, family history of cancer, and personal history 
(metachronous tumors) of cancer. Genetic counseling attendance rates of individuals with 
abnormal MSI/IHC results were compared and grouped by personal and family history factors 
versus other factors (Table 6). The classification was based on medical documentation review. 
The data reveals a significant difference (p = 0.0014; OR = 4.8; 95% CI: 1.78, 12.95) between 
 
 Saw GC No GC Total 
Females 33 (52.4%) 30 (47.6%) 63 
Males 11 (32.4%) 23 (67.6%) 34 
Total 44 53 97 
 Underwent Genetic Testing 
Genetic Testing 
not completed Total 
Female 28 (84.84%) 5 (15.15%) 33 
Male 9 (81.81%) 2 (18.18%) 11 
Total 37 7 44 
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the proportion of individuals who attended at a genetic counselor with a family or personal 
history compared to those with other factors. 
Table 5. Classification of Bethesda Criteria individuals with abnormal MSI/IHC after medical history review  
 
 
Females 
attending 
GC 
Females 
not 
attending 
GC 
Total 
Males 
attending 
GC 
Males 
not 
attending 
GC 
Total 
Age as factor 
(BI) 
 
3 
(37.5%) 
5 
(62.5%) 8 2 (25%) 6 (75%) 8 
Pathological 
factor (BIII) 3 (30%) 7 (70%) 10 
1 
(14.28%) 
6 
(85.72%) 7 
Family History 
of Cancer 
(BIV, BV, 
AMS) 
13 
(68.4%) 
6 
(31.6%) 19 
6 
(54.5%) 
5 
(45.5%) 11 
Personal 
history of 
HNPCC cancer 
(metachronous) 
6 
(85.72%) 
1 
(14.28%) 7 2 (40%) 3 (60%) 5 
Total 25 19 44 11 20 31 
*GC = genetic counselor 
 
Table 6. Individuals with abnormal MSI/IHC results grouped by factor 
 Saw GC No GC Total 
FH or PH 27 (64.3%) 15 (35.7%) 42 
BI and BIII 9 (27.3%) 24 (72.7%) 33 
Total 36 39 75 
* PH = Personal History; FH = Family history 
Among individuals who had an abnormal tumor test and saw a genetic counselor, the 
average difference between tumor testing and seeing a genetic counselor was 63 days, with 
83.33% of individuals seen within 90 days (3 months) of tumor testing. 
Individuals with abnormal MSI/IHC testing were further evaluated for other factors that 
might influence genetic counseling compliance including number of at-risk family members 
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(Table 7) and the type of cancers reported in the family (Table 8) based on medical history 
review.  The Cochran-Armitage test was performed to assess genetic counseling compliance was 
associated with (1) having no at-risk siblings or children, (2) having children or siblings at risk, 
or (3) having both children and siblings at risk, having, and having neither children nor siblings 
at risk.  There was no significant difference among these groups , (|Z| = 0.4626). However, 
genetic counseling compliance was associated with type of cancer (p = 0.0167); individuals with 
a family history of colorectal cancers were more likely to seek genetic counseling.  
Table 7. At-risk family members of those with abnormal MSI/IHC results based on medical history review 
 Children only Siblings only Both Neither Total 
Saw GC 11 (29%) 7 (18.4%) 15 (39.5%) 5 (13.1%) 38 
Did not see 
GC 10 (20.4%) 10 (20.4%) 18 (36.75%) 11 (22.45%) 49 
Total 11 17 33 16 87 
 
Table 8. Number of cancers reported in family history for individuals with abnormal MSI/IHC results 
 
# of colorectal 
cancers 
reported 
# of HNPCC 
associated 
cancers reported 
# of other 
cancers 
reported 
Total 
Saw GC 34 (60.7%) 16 (28.6%) 6 (10.7%) 56 
Did not see 
GC 22 (43.1%) 12 (23.5%) 17 (33.3%) 51 
Total 56 28 23 107 
 
The number of abnormal MSI/IHC results in the Bethesda Criteria population and 
identified by pathologists or surgeons or based on family history are presented in Table 9. Data 
was based on three criteria including whether patients were identified by only family history 
criteria (BIV, BV and metachronous HNPCC-associated cancers) or by pathological or surgical 
criteria (BIII and synchronous tumors). The last classification was whether individuals were 
identified by standard patient information documentation (BI) or possessed both pathological, 
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surgical or family history features, either of which would have prompted MSI/IHC testing.  The 
data elucidates the importance of both family history and the role of pathologists and surgeons in 
identifying at-risk patients, as each independently identified approximately 20-25% of at-risk 
individuals.  
Table 9. Identification of Bethesda Criteria individuals with abnormal MSI/IHC results 
 Family History 
Pathological or 
Surgical 
Identified by 
both or <50 y Total 
Abnormal MSI/IHC 
Bethesda Population 19 (24.1%) 17 (21.5%) 43 (54.4%) 79 
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6.0  DISCUSSION 
The central aim of the study was to assess the efficiency of the UPMC with referrals of at-risk 
HNPCC individuals to genetic counselors. Compared to a previous study of high-risk colon 
cancer patients, in which 30% of eligible patients attended a genetics clinic (Overbeek, 
Hoogerbrugge et al. 2008), the current study revealed an increased frequency of patients who 
attended a genetics clinic. Among 97 individuals who were eligible for genetic counseling as a 
result of abnormal MSI/IHC testing including both Bethesda and non-Bethesda individuals, 
45.3% (n=44) met with a genetic counselor at a UPMC facility. This study possesses several 
inherent limitations that influence interpretation of results. The lack of patient attendance to 
genetics clinic may be due to various reasons, and the primary assumption is that patients 
received referrals from clinicians. Additionally, these results reflect a problem in tumor test 
result interpretation and appropriate, subsequent referrals. The low frequency of eligible 
individuals attending a genetics clinic in the UPMC system indicates a possible breakdown in 
communication between pathologists, surgeons, clinicians and patients.   Thus, there is an 
opportunity to improve the referral process in order to identify and counsel a greater number of 
at-risk individuals. One factor that might influence the low frequency of individuals being 
counseled is that the University of Pittsburgh Medical Center does not have a defined protocol to 
channel at-risk colorectal cancer patients to a counseling service or to a single service location. 
The data collected for the study was from a cohort of individuals, seen by UPMC 
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gastroenterologists, oncologists, or surgeons and subsequently underwent MSI/IHC testing at a 
UPMC facility or attended a UPMC high-risk colorectal cancer clinic. The referral to high-risk 
clinics or genetic counselors was at the physician’s discretion. The results of this study indicates 
a clear need for a more comprehensive approach to patient care in the UPMC system, in which a 
large scale, high-risk cancer clinic with an institutional referral process should be established.  
The development of a comprehensive high-risk colorectal clinic at UPMC would 
unquestionably be considered a public health service. The clinic would provide the essential 
functions that define public health and its goals. The high-risk clinic would provide and connect 
patients with appropriate care. Those attending the clinic would engage in discussions and be 
educated about colorectal cancer, heritability, genetic testing, result implications, medical 
management options, and general colorectal cancer information including behavior and lifestyle 
recommendations. The clinic will provide patients with information on community resources, 
events and support groups. The clinic would be able schedule or refer patients for medical 
appointments, supply medical documentation for insurance providers and build relationships 
with patients for continued care purposes. As a result, the high-risk clinic will be an integral 
component of patient care within the community and UPMC system. 
Another component of public health is maintaining personnel competency in order to 
provide a high level of quality care. It is imperative that the high-risk clinic organizes education 
and review sessions for staff. Updated information on colorectal cancer, hereditary polyposis and 
non-polyposis disease practice guidelines, guidelines, current research, disease facts, new or 
altered policies and community resources should be communicated regularly with involved 
parties. The sessions will provide opportunities for deliberation about current protocols and areas 
requiring further consideration or development. 
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Instituting a new program that provides care to a sizeable population requires the 
education and empowerment of the community. Therefore, the high-risk colorectal cancer clinic 
should consider educational interventions that will provide information to health care providers, 
community members, and other clinics in order to market its services and potentially identify 
high-risk families not referred through the UPMC system. By increasing community awareness 
of hereditary cancer risk and the benefits of genetic counseling, it empowers patients to further 
investigate their family history and independently contact the high-risk clinic.  The clinic will be 
able to raise general awareness about colorectal cancer and screening in the community. 
Interventions to consider include participation in local or institutional health fairs, dissemination 
of informational pamphlets, develop a website and create social media outlets. 
Policy development for the purposes of public health will also be fulfilled by the clinic. 
Institutional policies related to the consent process, tissue testing, result reporting and patient 
referral would result in standardized process across the system. Collaboration between 
representatives of the high-risk colorectal cancer clinic and UPMC policy officials should occur 
in order to discuss policy requirements and potential obstacles as the process would be aided by 
institutional buy-in. As previously discussed, a standardized UPMC referral process to the high-
risk colorectal cancer clinic would permit the utilization of this important institutional resource. 
The comprehensive care of colorectal cancer patients in the UPMC system and subsequent 
policies will permit accurate monitoring and data analysis of several components of colorectal 
cancer and HNPCC in the region. 
Other public health essential service criteria that would need to be satisfied are the 
identification and mobilization of stakeholders. The success of the UPMC high-risk colorectal 
cancer program will undeniably require partnerships between several groups of health care 
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practitioners. Relationships between UPMC pathologists, surgeons, clinicians, oncologists and 
the high-risk clinic needs to be developed for appropriate referrals of patients with family history 
of colon cancer, abnormal MSI/IHC results, young-age onset disease or increased number of 
colonic polyps.. A prohibitive upstream factor of attendance with genetic counselors may be 
access to services. By establishing supplemental satellite clinics or teleconferencing sessions in 
western Pennsylvania, access to genetic counselors for patients that are farther removed would 
increase. Formulating affiliations with other high-risk cancer clinics in the UPMC system will be 
integral to comprehensive care of patients at-risk for HNPCC. Current recommendations for 
gynecological tumor testing for HNPCC requires excellent communication and involvement of 
gynecological clinics and practices within the UPMC system. Additionally, formalized 
interactions with laboratory technicians and directors may need to be considered. UPMC labs are accredited by Clinical Laboratory Improvement Amendments (CLIA), therefore, processing genetic testing for HNPCC on-site could significantly reduce the cost of testing for patients.  
Stakeholders not directly involved in patient care will also need to be mobilized to 
address other factors and improve the efficacy of the high-risk program. Genetic testing costs 
may preclude individuals from attending clinics or undergoing genetic testing. Collaboration 
with insurance companies, community and support groups, as well as local or organizational 
grants may subsidize costs of genetic testing. Additionally, the implementation of the high-risk 
program would result in greater numbers of individuals being apprised of genetic testing options 
and potentially electing for testing. It would be prudent to discuss the opportunity for economic 
growth with genetic testing companies in order to potentially drive down testing costs.  
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As outlined, many components of the program innately fulfill the public health service 
requirements, while some still need to be developed. Nonetheless, as a public health service, the 
high-risk colorectal cancer program will be a tremendous addition to the UPMC system and the 
surrounding community. 
Organizing a restructured comprehensive UPMC protocol for at-risk cancer patients may 
aid health care practitioners. Placing the responsibility of genetic counseling service referral on a 
single care provider may be overwhelming and laborious and reduce efficiency of the process.  
Because numerous health professionals are accountable for the care of a patient, members of this 
team should share the responsibility in indentifying appropriate candidates for additional testing 
and referrals. Therefore, one approach would be to bestow on pathologists a greater 
responsibility in the referral process. As the knowledge and association between molecular 
diagnostics and genetics continues to unfold, the role of pathologists in the care of patients will 
undoubtedly increase. The role of pathological markers in hereditary colon cancer is well 
documented and the importance of pathological markers has also been illustrated in other fields 
as well. For example, studies have shown that specific morphological features of breast cancer 
tissue are more likely to be present BRCA1 carriers versus non-carriers. Therefore, the presence 
of these features in a patient has been proposed as biomarker for increased risk and a 
recommendation for clinicians and pathologists to refer the patient for genetic testing (Gadzicki, 
Schubert et al. 2009). Likewise, metabolic storage disorders and hemoglobinopathies identified 
by pathology studies of placental tissue are examples of diagnoses initiated by pathologists. The 
involvement of pathologists in identifying at-risk individuals is not only a method of early 
detection of genetic diseases, but also has implications for genetic counseling and future 
pregnancies (Oppitz, Klee et al. 2009; Staretz-Chacham, Lang et al. 2009). Therefore, in order to 
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improve the rate of referrals to genetic counselors, the roles of pathologists in disease recognition 
should be better utilized.  
One way to coordinate a functional, efficient method of communication between current 
and future health care providers could include a process whereby the notification of abnormal 
MSI/IHC test results is directly reported to genetic counselors from the pathologists. This 
strategy would allow counselors to engage in discussions with patients, facilitate appointments, 
clarify test results, and address other pertinent information if necessary. A previous study 
assessing patients that were contacted regarding genetic counseling services by mail had a 
response rate of 26% (Keller, Jost et al. 2004). Although, the low response rate suggests that this 
method of contact is less than ideal, it may be utilized as a supplement to the current system to 
increase the number of high-risk patients attending genetic counseling. An automated computer 
system could be configured to notify genetic counselors of abnormal test result. The process 
could address some of the obstacles of referral by reducing the workload of pathologists and 
treating practitioners without a loss of information delivery. The counselor-initiated process also 
avoids the potential constraint of relying on an intermediary source to recognize the need for and 
broach the issue of genetic counseling. However, the importance of conversations between 
patients and treating practitioners should not be overlooked as data indicates that patients whose 
treating practitioners discussed referrals to a genetics clinic attended more frequently (Overbeek, 
Hoogerbrugge et al. 2008). Therefore, it is necessary that both genetic counselors and clinicians 
play an active role in the process of patient referral and attendance at a genetics clinic. 
If a counselor-initiated method were implemented, there are several issues to consider. 
Introducing the issue of genetic referrals or discussing genetic test result implications with 
individuals during the time surrounding cancer diagnosis may be overwhelming for both the 
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patient and family. As genetic testing may have implications for surgical decisions, counselors 
must balance attempting to contact patients prior to surgery and respect for patients’ right to 
privacy during a difficult time. Genetic counselors that make contact with patients need to have a 
heightened sensitivity for patient emotions and be prepared for a variety of responses. As every 
patient will cope with the situation differently, genetic counselors’ attuned skills for assessing 
patients’ signals will allow them to determine appropriate questions to ask, issues to probe and 
gauge whether patients are emotionally ready for a detailed discussion. For these and many other 
reasons, genetic counselors are well equipped to reach out to these at-risk patients during this 
emotional time.  
It is imperative that alterations to the informed consent process occur if counselors are the 
ones contacting patients. The patients must be informed and consent to the disclosure of 
information to other appropriate health care practitioners, which would require patient sanctioned 
communication between pathologists, health care and genetic service providers. The concept has 
been noted in a previous study, where it was recommended that colorectal cancer patients seen in 
clinic for treatment or diagnosis should be briefly counseled on the heritability of colorectal 
cancer and that testing on the tissue will be carried out in order to determine the possibility of 
this risk (Chubak, Heald et al. 2011). The authors further elaborate that patients be notified that 
they will be contacted by a genetic counselor or other health care practitioner to discuss their 
results, define familiar risk or make appropriate referrals (Chubak, Heald et al. 2011). Informed 
consent and written authorization to share patient information with other health care providers 
would obviate violations of HIPAA laws or other confidentially issues. Moreover, informed 
consent and pre-test counseling may influence genetics clinic attendance. Studies have revealed 
that educational materials and decision aids, including computer-based resources, provided to at-
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risk patients prior to MSI testing improved patients’ comprehension of tests implications for 
themselves and family members. The material also increased patients’ preparedness in making 
informed decisions about MSI testing (Manne, Meropol et al. 2010). Therefore, provision of 
education materials or appropriate counseling prior to MSI testing may increase the proportion of 
patients attending a genetic counseling appointment if indicated. 
Another benefit to the adjusted consent process would allow for counselors to call to 
discuss implications of negative test results. Although obtaining a negative MSI/IHC result 
reduces the likelihood of the presence of a hereditary cancer syndrome, close family members of 
affected individuals are at an increased risk to develop the disease compared to those in the 
general population without a family history. Grady et al (2003) report that individuals with a first 
degree relative with colon cancer are twice as likely to develop colon cancer compared to 
individuals without a family history of colon cancer. The risk would become more elevated for 
those with more than one affected close family member. The current study indicates that just 
over 10% of individuals diagnosed prior to age 50, had a close family member diagnosed with 
colorectal cancer or an HNPCC associated cancer.  The American Cancer Society has outlined 
screening guidelines for all individuals with a family history of colon cancer, that also would be 
pertinent for family members of at-risk individuals whose tumor tests results are not abnormal. 
Although the time required to properly communicate all the pertinent information may not be 
feasible, providing supplementary information in the counseling session or through educational 
material, as mentioned previously, is not unreasonable. Thus, discussions with counselors, 
provision of educational materials to patients and families on sporadic, hereditary, and familial 
cancers prior to or after testing, may serve to promote family members to seek earlier cancer 
surveillance because of their increased risk compared to the general population. 
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A standardized process utilizing automated computer software would benefit system 
resources and it may have additional clinical applications as well. As the utilization of electronic 
health information systems evolves and becomes more prevalent, interventions founded on the 
technology could be implemented to benefit the quality of treatment patients are provided. An 
electronic notification system would be a practical application of the technology to signal 
physicians on a variety of facets of patient care including abnormal test results, clinical 
diagnoses, research eligibility, referrals, general inquiries or topics for discussion. For the 
purposes of identifying HNPCC individuals, the software program could notify health care 
providers of individuals meeting a criteria for MSI/IHC testing, a clinical diagnosis of 
Amsterdam I, and those requiring a referral to a genetics clinic. Previous studies have 
investigated the utilization of an electronic alert system for notifying physicians of clinical trial 
availability based on electronic patient health information. The study reported a significant 
increase in patient referral by physicians that responded to the electronic alert and also found that 
85% of those physicians were amenable to the notification process. Additionally, even the 
majority (66%) of those physicians who did not utilize the alert, appreciated the electronic 
reminder (Embi, Jain et al. 2008). The study demonstrated that the electronic reminder system is 
an effective tool for increasing the number of physician-referred patients to clinical trials, and the 
concept should be readily translatable to genetic services. The study further elaborated that the 
limitations of the process to include the presence of a functional electronic health records system, 
shortcomings of the notification, as well as physician acceptance and utilization. 
The current study also assessed the time interval between tumor testing and attendance 
with a genetic counselor. The data revealed that individuals who attended with genetic 
counselors were seen on average within two months of tumor testing, with over 80% of 
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individuals seen within three months. The data suggests that it is imperative to begin the process 
of referring to a genetic counselor soon after testing. In order to accomplish this, a potential plan 
could include having genetic counselors present or available when treating practitioners disclose 
abnormal MSI/IHC test results, so that patients could be seen during the same appointment. 
Patients may be psychologically unprepared for immediate conversations about hereditary 
factors of their cancer or time restrictions may preclude additional appointments; however, 
counselors can be available during subsequent follow-up visits. Unfortunately, the busy clinic 
schedules of genetic counselors and the variety of medical locations where patients are seen for 
test result disclosure are major obstacles to the “stand-by” genetic counseling concept. However, 
by centralizing genetic counseling resources to a high-risk clinic and establishing a regulated 
process of patient referral or recruitment to the clinic could improve the proportion of at-risk 
individuals seen by genetic counselors within the UPMC system.  
Understandably, enhancing the referral process may not necessarily correlate to a 
significant improvement in attendance to a genetic counseling service as a lack of patient 
compliance to medical recommendations is an obvious impediment in attaining the goal of 
complete attendance. Patients have several reservations regarding genetics and genetic testing 
that may preclude them from seeking genetic counseling. These reservations include a lack of 
knowledge about genetic testing and counseling services, concerns regarding genetic 
discrimination, and concerns regarding autonomy and handling of personal and genetic 
information (Martin, Greenwood et al. 2010). Availability of resources also play a role because 
limited access or insufficient financial support for genetic services can influence an individual 
from obtaining applicable and appropriately timed services. As observed in the current study, 
financial limitation was the most reported factor for not undergoing genetic testing. Distress 
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regarding familial implications and disclosing information to close family members, including 
children, has also been frequently documented as reasons for skepticism regarding seeking 
genetic services (Martin, Greenwood et al. 2010). 
Another objective of the study was an analysis of the family history collection of UPMC 
practitioners. The data elucidates an opportunity for improvement in its attainment as 60 
individuals met an additional Bethesda Criteria with a more personal or family history criteria 
component when medical history documentation was reviewed. Specifically, nearly 5% and 10% 
of individuals meeting Bethesda I and Bethesda II Criteria, respectively, met Amsterdam II 
Criteria after review of medical history documentation. Currently, there are no clinical guidelines 
for individuals who meet the Amsterdam II Criteria, however, with more detailed family history 
collection, an increase in the identification and follow-up of families meeting the Amsterdam II 
Criteria may result in more accurate risk estimates and potential clinical screening guidelines for 
this population. Additionally, improved family histories may result in more compelling 
genotype-phenotype associations between specific Bethesda Guidelines or family history criteria 
and germline MMR mutations, which may eventually initiate discussions campaigning for direct 
DNA analysis or focused gene-specific testing on certain individuals as a way to increase cost-
efficiency.  
The shortcoming of extensive family history attainment has notable clinical impacts on 
other individuals. Failure to identify Amsterdam I criteria family members is a crucial misstep 
from a medical management standpoint, as these families, given an abnormal MSI/IHC result, 
would be provided altered medical management opportunities. Familial colorectal cancer type X 
families would be considered for increased screening for colon cancer and therefore, the clinical 
diagnosis of Amsterdam I Criteria families is an important step for clinicians to undertake for 
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patient care purposes irrespective of genetic test results. Amsterdam I Criteria patients that do 
not receive genetic counseling referrals, or do not attend genetics appointments or choose not to 
have genetic testing should still be engaged in conversations about alternative medical 
management options. As previously discussed, family history has clinical implications for 
individuals of non-HNPCC family members affected with colorectal cancer therefore, improved 
cancer history collection may be critical for screening recommendations of unaffected family 
members.  
As individuals with a family history were more likely to attend a genetics clinic, the data 
also identifies a group that requires additional attention. Individuals with a lack of family history 
may perceive themselves at a lower risk as seen in the relatively low number of individuals 
(31%) who met only the Bethesda I Criteria attending at a genetic counseling appointment. 
However, this study reveals that when medical documentation is further investigated 
approximately 17% of individuals under the age of 50 met other family history-based Bethesda 
criteria. Efforts should be made to engage this group more intensely in an attempt to stress 
features about hereditary cancer syndrome that may be important for the patient and other family 
members. Characteristics that reduce cancer prominence in a family, including small families, 
reduced penetrance of the disease, early ages of death, may be important to discuss with this 
population. Likewise, the issue of reduced cancer penetrance is critical for treating practitioners 
as well, especially when obtaining a detailed family history. Among the issues previously 
mentioned, one that can be overlooked in familial cancer syndrome families, specifically 
HNPCC, is prophylactic surgeries. Risk reducing procedures can lead to the perception of lower 
risk by both health care providers and patients. It is important for health care providers to inquire 
about surgeries when obtaining family histories. 
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Another important reason for obtaining detailed family histories for individuals at risk for 
HNPCC, is that by obtaining the information it may guide health practitioners towards other 
differential diagnoses and genetic testing. Alternative colon cancer syndromes are identified 
through marked presence of polyps, however attenuated polyposis syndromes may be difficult to 
differentiate from HNPCC. It has been documented that 6.1% and 2.8% of individuals that are 
diagnosed with colon cancer below the age of 50 and 55, respectively, have been identified to 
have MYH-Associated Polyposis (Fleischmann, Peto et al. 2004; Balaguer, Castellvi-Bel et al. 
2007). The former is important as these individuals meet the Bethesda I Criteria for MSI testing. 
Therefore, individuals with a lack of family history or those with a recessive inheritance pattern 
should be considered for MAP. Additionally, for the purposes of identifying differential cancer 
diagnoses, health care practitioners should be educated on characteristics other than cancer to 
investigate within families. Inquiries regarding features including skin manifestations, such as 
those observed in the HNPCC variant Muir-Torre or in Cowden Syndrome, may reveal 
information that would influence or focus patient care, testing and referrals, resulting in a more 
cost-effective process. Additionally, more detailed family histories may help to identify other 
non-cancer syndromes in the family that may require discussion.  
Although the current EGAPP recommendations may influence the importance of family 
history taking for identifying at-risk HNPCC individuals affected with colorectal cancer, the 
study data reveals that family history can still play a role in various components of patient care. 
Our data suggests that individuals who have a strong personal or family history of cancer were 
significantly more likely to attend genetic counseling sessions if they were found to have 
abnormal tissue testing. The elevated compliance in individuals with a stronger family history is 
a reasonable finding and has been seen in other cancer syndrome studies (Gadzicki, Schubert et 
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al. 2009). Unfortunately, as family histories were obtained and pieced together through a review 
of medical history documentation, the exact influence of obtaining family history is unclear. 
However, one could surmise that obtaining a more detailed family history with associated 
discussions may serve to better enlighten patients on the potential hereditary factors of similar 
and associated cancers, thus increasing patient compliance with referrals to genetic counselors. 
Therefore, the collection of a more detailed family history is vital for comprehensive patient care 
and reduced patient and institutional costs. 
Other potential influencing factors of individuals who attended genetic counselors were 
assessed including the presence of non-colorectal cancers in family history and the presence of 
at-risk family members. The presence of colorectal cancer, HNPCC-associated cancers and non-
HNPCC cancers were assessed in order to determine their impact on genetic counseling 
attendance. The data suggests that the prevalence of colorectal cancer in families compared to 
those with non-HNPCC associated cancers may influence the likelihood of attending with a 
genetic counselor. While the data indicates that individuals with a stronger personal or family 
history were more likely to attend genetic counseling appointments, reduced genetic literacy may 
play a vital role in the perception of risk in families with non-HNPCC related cancer history. 
Families may not be apprised of the association of specific cancers in the family due to the 
prevalence of numerous disparate types of cancer. Genetic counselors are skilled at filtering 
through extensive family cancer histories with patients and discussing relatedness of certain 
cancers in the family to explain risk for hereditary syndromes. As such, front-line health 
practitioners may need to address diverse and substantial family cancer histories by promoting 
the ability of genetic counselors to dissect it. Although the data does not support the idea, a 
similar effect could potentially be seen in families with extra-colonic HNPCC-associated 
 69 
cancers. Families may recognize the relationship between similar cancers in a family and the 
potential for a hereditary syndrome, but the presence of cancer in various, seemingly 
unconnected organs may not be as apparent to the population. Therefore, education of 
individuals with family history of extra-colonic HNPCC associated cancers and the relatedness 
of those cancers due to a hereditary syndrome may be integral to their perception of risk and, 
thus, may influence their likelihood to attend at a genetics clinic. Further research should address 
determining whether the presence of a strong family history of cancer alone is the driving 
element in attendance with a counselor, or whether the protraction of the family history and 
discussion of relatedness of cancers is the motivating factor for patient compliance with genetic 
referral.  
Another factor that was considered for influencing patient attendance at a genetic 
counseling appointment was the presence of at-risk family members. Medical documentation 
was reviewed to determine which individuals had siblings and children that may be affected by 
genetic testing results. When grouped for at-risk family members, the data did not reveal any 
trends in genetic counseling attendance rates between those with no at-risk siblings or children, 
those with both at-risk siblings and children, and those with either siblings or children at risk. 
The data appears to undermine the concept that individuals are motivated to undergo testing to 
help at-risk family members, however the small sample size may have impacted these results. 
However, the number of at-risk family members was not assessed in this study and this may 
prove to be significant for influencing attendance with a genetic counselor. 
An additional aim of the research was to reveal the methods of identification of at-risk 
HNPCC individuals. The identification of an individual with HNPCC requires the contribution 
of numerous health care practitioners at a multitude of checkpoints along the way. Primary care 
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providers, surgeons, oncologists, pathologists, and geneticists all play a role in the care, 
management, treatment and identification on an individual with HNPCC. One of the goals of the 
study was to assess the importance of both pathological and family history factors in identifying 
at-risk individuals. This was accomplished by categorizing the method of identification into 
solely pathologically or surgically based, family history based, patient intake information or a 
combination of multiple factors. The data reveals that pathologists and clinicians independently 
identified approximately 20-25% of individuals meeting a Bethesda Criteria, who would have 
otherwise gone unrecognized. The data emphasizes the importance of both pathologists and 
clinicians, separately and as a health care team. The data suggests that the presence and role of 
both groups providers are integral, and the absence of either party would result in a reduction in 
the effectiveness of the process. However, given that the current guidelines indicate that all 
colorectal cancer tissues undergo MSI or IHC testing, the responsibility of both groups to 
identify at-risk individuals has consequently been altered. The benefits of the change in protocol 
will noticeably include the recognition of HNPCC individuals that are missed by the Bethesda 
Criteria. Conversely, the limitations may not be as conspicuous. An increased number of tumors 
undergoing molecular testing will put pressure on health professionals carrying out these tests. 
Additionally, the role of family history in affected individuals has shifted away from identifying 
at-risk individuals and transformed into having a greater emphasis on other aspects of patient 
care including potentially influencing compliance with genetic counseling referrals, as discussed 
above. 
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7.0  STATE-WIDE REFERRAL SYSTEM 
The implementation and success of the high-risk colorectal cancer program in Pittsburgh may 
lead to greater downstream effects. The cost-effectiveness of colorectal tumor screening in 
identifying HNPCC individuals on a local level should facilitate recommendations for population 
screening program funded at a state and, potentially, federal level. Additionally, the program is 
an ideal opportunity to implement genetic and genomics knowledge to improve health care and 
health policy.  
As discussed previously regarding the high-risk clinic at UPMC, colorectal cancer 
screening fulfills the essential public health functions for many similar reasons. A large-scale 
tumor screening and referral program would necessitate assessment of policy development and 
quality assurance for colorectal cancer and HNPCC screening. Similar to other screening 
programs, the testing of colorectal cancer tumors will provide comprehensive societal 
information on disease prevalence of colorectal cancer and HNPCC. The increase in testing, 
especially in underserved populations, will produce an abundance of information on variants of 
uncertain significance, cancer risks and prevalence in these communities. Additionally, the 
information obtained on such a large scale will provide insight on the efficacy of the screening 
and community education programs and other interventions on reducing the incidence or effect 
of colorectal cancer in the population. 
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Genetic testing interventions for the purposes of clinical care are meticulously scrutinized 
for several key components. With regards to HNPCC testing, the analytic validity, clinical 
validity, clinical utility, and diagnostic testing has proven to be of high quality (I.O.M. 2010). As 
such, it seems appropriate to juxtapose the proposed screening program to other genomic 
screening programs, most notably, the Newborn Screening (NBS) program. With the inception 
of the NBS, a set of screening criteria drafted by Wilson and Jungner outlined determinants of a 
disease that should be met to be included in the screening program (Wilson and Jungner 1968). 
The criteria included: the presence of a pertinent health issue, accepted treatment for the 
diseased, available diagnostic services, facilities to receive treatment, comprehension of the 
natural history of the disease, early or pre-symptomatic stages of the disease and testing that is 
accepted by society. Colorectal tumor testing meets the majority of these criteria for population 
screening of HNPCC. The significant prevalence of colorectal cancer in the United States, and 
considerable proportion deriving from HNPCC, as well as the increased risk for other HNPCC 
associated cancers makes it an important health issue. The reduction in mortality and morbidity 
from supplemental medical management options such as increased screening and prophylactic 
surgery for HNPCC can be interpreted as treatment for diseased individuals. Additionally, the 
aforementioned medical procedures, as well as tumor testing and genetic testing, are available 
throughout the state and screening can lead to identification of pre-symptomatic mutation 
carriers who are eligible for similar services. Furthermore, extensive HNPCC research has 
broadened the knowledge surrounding disease characteristics and progression. Currently, 
colorectal tumor testing is already carried out on select individuals and is widely accepted as few 
individuals decline testing after consent.  
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However, the aforementioned benefits require an implementation protocol for testing as 
well as referral to genetic counseling. One of the most salient issues for the effectiveness of 
population colorectal tumor testing is that the program will target unaffected HNPCC family 
members. Increased screening and surgery can reduce cancer sequelae for affected individuals; 
however, the greatest impact will be observed in screening family members for disease 
prevention. A previous study of unselected colorectal cancer patients found that those with 
HNPCC had an average of greater than three relatives diagnosed with the mutation (Hampel, 
Frankel et al. 2008). The value of the program is greatly compromised if affected individuals are 
not referred for counseling and if at-risk family members are not informed about the potential for 
a hereditary cancer risk. However, there are several ethical dilemmas with communicating risk to 
third-party family members by health care practitioners, such as patient confidentially and duty 
to warn. Discussions with a genetic counselor can mitigate some of these concerns.  Furthermore 
studies have shown that after a genetic counseling session, there is a cascade effect in HNPCC 
families where five to six relatives per proband subsequently undergo genetic testing (Hampel, 
Frankel et al. 2005). Therefore, standardized consent approaches and rigorous education 
programs should be developed to emphasize the implications of tumor testing for family 
members to improve communication in families. Moreover, a screening program run at a state 
level may be able to circumvent the fragmentation of the health care system. Irrespective of 
service provider, affected individuals and their at-risk family members would obtain tumor 
screening and referrals for genetic counseling services. 
The effectiveness of the program requires reaching as many at-risk individuals as 
possible.  MSI testing has the potential to affect a greater proportion of individuals as part of a 
population-screening program. MSI testing has various, potential applications, while IHC testing 
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is only useful to identify non-functioning MMR proteins for germline testing. However, for a 
large-scale program, IHC testing is more cost-effective due to its wide accessibility and resultant 
targeted genetic testing. Therefore, opt-in and opt-out policies for MSI and IHC testing could be 
considered as an alternative. Those opting out of testing reduce the effectiveness of the screening 
program, however, the infringement on patients’ rights are potentially avoided. 
To determine cost-effectiveness of a screening program, Mvundura et al (2010) compared 
different screening strategies for HNPCC on a population-wide and age-specific level, and also 
considered all associated costs and risks. Using relatively conservative values for HNPCC family 
members that would be contacted as a result of screening program, they calculated the number of 
life years (LY) saved. The data was used to determine the incremental cost-effectiveness ratios 
(ICER), total cost per LY. The study revealed that population screening utilizing a preliminary 
test, MSI or IHC, yielded ICER ranges within accepted values for implementation. The most 
cost-effective method of IHC testing, BRAF testing and subsequent germline sequencing yielded 
values closer to that of general population screening for colorectal cancer in those 50 years of 
age and older. However, the study did not include the cost-effectiveness of screening other 
HNPCC-associated cancers or prophylactic surgery, which may have further improved the 
numbers. The study did not evaluate the cost-effectiveness of implementing both MSI and IHC 
testing. However, one would surmise that testing for both MSI and IHC would decrease the 
effectiveness of the program due to the increased costs associated with performing both tests 
(Mvundura, Grosse et al. 2010).  
The cost-effectiveness of the population-screening program has been further corroborated 
from a provider’s perspective. The study also supported the IHC preliminary testing in order to 
maximize efficiency (2010). Additionally, the study indicated that although subsidized genetic 
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testing of the proband is costly, there is potential for financial benefit. As the overlying goal is to 
reduce morbidity and mortality in unaffected HNPCC individuals, genetic testing of affected 
individuals is essential to identifying familial mutations. Subsequent single-site testing for family 
members is much more affordable and would cause an influx of patients into the health system. 
Increases in screening frequencies of unaffected individuals would also be profitable. 
Additionally, while screening is currently limited to colon tumor, there is potential for a similar 
screening program expanding into gynecological tumors. 
A screening and referral program on a state level has the opportunity to benefit a variety 
of involved parties from both a financial and health perspective. Imminent developments in 
genetic technology make it even more essential to develop and establish a screening and referral 
process on a large scale. This intervention can serve as a foundation or model for similar genetic 
programs. 
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8.0  STUDY LIMITATIONS 
There are several marked shortcomings of the current study that will be elaborated upon, 
however, the general composition of the study population appears comparable to other 
populations. Approximately 20% of individuals meeting Bethesda criteria in our study had an 
abnormal MSI/IHC, which is similar to a larger study conducted on 1,721 individuals meeting 
the Bethesda Criteria where 23.6% of tumors displayed microsatellite instability (Mangold, 
Pagenstecher et al. 2005). The obvious shortcoming of the study is that the analysis of the data 
was based on review of provided medical documentation. The completeness of the data obtained 
affects the accuracy of several aspects of study including clinician referrals, molecular and 
genetic testing completed, personal and family surgical history and personal and family cancer 
history. Consequently, the comprehensiveness of documents was a considerable limiting factor. 
Moreover, medical information on the number of children in the family was easier to ascertain 
for women within the study compared to men. Additionally, many women are known to be the 
gatekeeper with regards to family medical information, which may have resulted in stronger and 
more detailed family histories compared to men. Moreover, medical reports obtained and 
reviewed were restricted to those found in the UPMC system. As a result, individuals who 
reported more detailed family histories, sought follow-up genetic counseling services or genetic 
testing outside the UPMC system would result in an underrepresentation of the data. Limited 
patient information restricted the geographical origin of patients, precluding inferences about the 
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number of out of the area patients that may have been assessed elsewhere. Similarly, reduced 
patient adherence to physician recommendations may have played a role in the study and 
attributed to the reduced number of individuals seeking genetic counseling services. Data could 
not differentiate between those referred for genetic counseling but did not attend for unknown 
reasons, and those that did not receive a referral at all. Reasons for not seeking genetic 
counseling services could not be ascertained from the data, however, explanations may include 
apprehension for genetic counseling services, reservations about costs, feelings of guilt regarding 
familial risks, and limited access to genetic counseling services.  
As previously discussed, in the absence of corroborating medical information on family 
members, patient recall of family cancer history is a major obstacle in accurate risk assessment. 
Underreporting of cancer diagnosis within a family may result from communication breakdowns 
due to family dynamics or because of geographical separation. Other factors may also influence 
the type of cancer reported in families including a lack of literacy on the disease. The sinister 
feature of cancer is its ability to spread, and therefore, it can affect a profound number of tissue 
sites other than the site of origin. The affected tissue that ultimately leads to the demise of an 
individual may be the type of cancer reported by family members resulting in misguided family 
history documentation. Social networking sites have allowed families to connect with one 
another from across the globe. With the availability of information sharing and family history 
applications on these networking sites, an improvement of the accuracy and specificity of family 
medical history is inevitable, although health practitioners will still need to confirm many of 
reported diagnoses. An evolution in family history is taking place and we as health practitioners 
need to embrace and utilize it for improved patient care.  
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Another potential limitation of the evaluation was that the study cohort represents a 
selection bias as a proportion of the individuals were assessed at the High-Risk colorectal cancer 
clinic, whose focus on the recognition of hereditary colon cancer syndromes may have lead to 
more detailed family history documentation and identification of at-risk individuals. Physician 
prompted questioning and clinical environment may have influenced the accuracy of family 
history reporting. Individuals in attending a high-risk genetics clinic discussing the potential 
hereditary factors of cancer may be more inclined to report similar cancers within the family. 
Additionally, health practitioners’ probing for genetically associated cancers may ask about 
specific cancers which in turn could lead to individuals over reporting these syndrome associated 
cancers. Furthermore, patients assessed at a high-risk genetics clinic or by UPMC clinicians with 
special interest in hereditary cancer syndromes would be more cognizant of strong family 
history, abnormal test results and their possible implications. As a result, patients of these 
informed health care practitioners may be more likely to obtain referrals to genetics counseling 
services.  
Technological shortcomings are also observed in the study as the majority of patients that 
had immunohistochemistry testing, had MLH1, MSH2 and MSH6 proteins assessed. Therefore, 
as staining for PMS2 was not applied to these patients, pathogenic mutations in PMS2 gene may 
have been neglected. Studies indicate that approximately less than 4.3% of microsatellite 
unstable tumors display absent PMS2 proteins, without simultaneous absence of other MMR 
proteins (Senter, Clendenning et al. 2008). Additionally, a smaller number of individuals that had 
IHC evaluation were only tested for MLH1 and MSH2, thus overlooking the potential to identify 
MSH6 dysfunctional proteins. As previously discussed, a proposed initiative to move towards a 
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two-antibody system of MSH6 and PMS2, not only for cost effectiveness purposes, but also to 
capture mutations in these less prevalent MMR genes, may remedy this issue in future studies. 
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9.0  CONCLUSIONS 
The current study reveals there is an opportunity for the UPMC system to improve the genetic 
counseling process of individuals at risk for HNPCC. Suggestions have been outlined that could 
potentially address some of the current deficiency in the UPMC system. Alterations in referral 
protocols, clinical policies, and use of technologies may prove to have an impact on the issue. 
However, study suggests that the overall fragmentation of the health care system needs to be 
addressed by developing a single clinical pathway for at-risk patients to be managed.  
Several factors have been identified as potentially influencing the attendance of at-risk 
HNPCC individuals with a genetic counselor. The information uncovered in the study can be 
utilized by health practitioners to effectively discuss genetic counseling referrals with patients 
and address possible barriers to compliance. 
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